

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**





EUROPEAN PATENT APPLICATION

Application number: 84303128.7

Date of filing: 09.05.84

Int. Cl.<sup>3</sup>: C 07 D 487/04, C 07 D 499/00,  
A 61 K 31/40, A 61 K 31/43  
// C07D207/16, C07D207/24,  
C07D401/12, C07D205/08,  
C07F7/18,  
C07F9/65, (C07D487/04, 209/00,  
205/00)

Priority: 09.05.83 JP 81443/83  
15.06.83 JP 108472/83  
12.07.83 JP 127485/83  
26.09.83 JP 127485/83  
09.09.83 JP 166938/83  
11.11.83 JP 212857/83  
10.02.84 JP 23497/84

Date of publication of application: 28.11.84  
Bulletin 84/48

Designated Contracting States: AT BE CH DE FR GB IT  
LI NL SE


Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED,  
15 Kitahama 5-chome Higashi-ku, Osaka-shi Osaka-fu  
(JP)

Inventor: Sunagawa, Makoto SUMITOMO CHEMICAL  
COMPANY LIMITED, 1-98, Kasugadenaka 3-chome  
Konohana-ku, Osaka-shi Osaka (JP)  
Inventor: Matsumura, Haruki SUMITOMO CHEMICAL  
COMPANY LTD., 1-98, Kasugadenaka 3-chome  
Konohana-ku, Osaka-shi Osaka (JP)  
Inventor: Inoue, Takaaki SUMITOMO CHEMICAL  
COMPANY LIMITED, 1-98, Kasugadenaka 3-chome  
Konohana-ku, Osaka-shi Osaka (JP)  
Inventor: Fukasawa, Masatomo SUMITOMO CHEMICAL  
COMPANY LTD., 2-1, Takatsukasa 4-chome,  
Takarazuka-shi Hyogo (JP)  
Inventor: Kato, Masuhiro SUMITOMO CHEMICAL  
COMPANY LIMITED, 2-1, Takatsukasa 4-chome,  
Takarazuka-shi Hyogo (JP)

Representative: Diamond, Bryan Clive et al, Gee & Co.  
Chancery House Chancery Lane, London WC2A 1QU  
(GB)

Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof.

Penem compounds are of the formula:



where R<sub>1</sub> is H or hydroxyethyl, wherein the -OH may be protected

R<sub>2</sub> is H or a protective group, e.g. alkoxycarbonyl;

R<sub>3</sub> is H or a protective group, e.g. alkyl;

X is methylene or alkyl-methylene or S;

Y is amino (-NH<sub>2</sub>) which may be substituted by various groups which can form a ring.

Synthesis is from a beta-lactam derivative wherein the 2-position has a reactive ester alcohol group or alkylsulfinyl group, reacted with a pyrrolidinyl derivative in a solvent in presence of a base.

The compounds are useful as antimicrobial agents.





- 1 -

CARBOXYLIC THIO-PYRROLIDINYL  
β-LACTAM COMPOUNDS AND PRODUCTION THEREOF


This invention relates to novel β-lactam compounds and a process for producing the same. More particularly, this invention relates to novel β-lactam compounds which are carbapenem or penem derivatives and useful as antimicrobial agents or intermediates therefor and a process for producing the same.

Since the discovery of thienamycin having a potential antimicrobial activity against Gram negative and Gram positive bacteria, studies on syntheses of carbapenem or penem derivatives which are analogous to thienamycin have been widely developed.

The present inventors have conducted intensive investigations on syntheses of carbapenem or penem derivatives and, as a result, found that carbapenem or penem derivatives having, as their 2-side chain, a substituent easily derived from 4-hydroxy-proline, i.e., a substituted pyrrolidinyl group carrying a carbonyl group substituted with various substituents on its 2-position, exhibit potential antimicrobial activity and are useful as medicines or are important intermediates for compounds possessing antimicrobial activity, and

thus completed the present invention.

The present invention relates to a novel carboxylic  
β-lactam compound represented by the formula (I):



wherein  $R_1$  represents a hydrogen atom, 1-hydroxyethyl group  
or a 1-hydroxyethyl group in which the hydroxy group is  
protected with a protecting group;  $R_2$  represents a hydrogen  
10 atom or a protecting group for an amino group;  $R_3$  represents  
a hydrogen atom or a protecting group for a carboxyl group;  
X represents a substituted or unsubstituted methylene  
group of the formula (1):



wherein  $R_4$  represents a hydrogen atom or an alkyl group  
having 1 to 3 carbon atoms,

or a sulfur atom; and Y represents a group of the formula (2):



wherein  $\text{R}_5$  and  $\text{R}_6$ , which may be the same or different, each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 3 to 4 carbon atoms, an aralkyl group having 1 to 3 carbon atoms in its alkyl moiety, a substituted alkyl group having 1 to 5 carbon atoms or a pyridyl group, or  $\text{R}_5$  and  $\text{R}_6$  taken together represent an alkylene chain or an alkylene chain containing an oxygen atom, a sulfur atom or a  $(\text{C}_1\text{-C}_3)$ alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a substituted or unsubstituted 3- to 7-membered cyclic amino group which may contain double bond(s) in its ring, a substituted or unsubstituted guanidyl group of the formula (3):



wherein  $\text{R}_7$  represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, a protected or unprotected hydroxyl group, an alkoxy

group having 1 to 3 carbon atoms, an unsubstituted or (C<sub>1</sub>-C<sub>3</sub>) alkyl-substituted hydrazino group or a group of the formula (4):



5        wherein R<sub>8</sub> represents a hydrogen atom, a protecting group for a hydroxyl group or an alkyl group having 1 to 3 carbon atoms, and pharmacologically acceptable salts thereof; and a process for producing the same.

10

      In the above-described formula (I), the protecting group for a hydroxyl group as represented by R<sub>1</sub> and the protecting group for an amino group as represented by R<sub>2</sub> may be any of those commonly employed. Preferred examples of these protecting groups include a lower alkoxycarbonyl group, e.g., t-butyloxycarbonyl; a halogenoalkoxycarbonyl group, e.g., 2-iodoethyloxycarbonyl, 2,2,2-trichloroethyloxycarbonyl; an aralkyloxycarbonyl group, e.g., benzyloxy-  
20 carbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxy- carbonyl, p-nitrobenzyloxycarbonyl; and a tri-alkylsilyl group, e.g., trimethylsilyl or t-butyldimethylsilyl.

The protecting group for a carboxyl group as represented by  $R_3$  may be any of those commonly employed and preferred; examples are straight or branched chain lower alkyl group, e.g., methyl, ethyl, isopropyl, t-butyl; a halogeno lower alkyl group, e.g., 2-iodoethyl, 2,2,2-trichloroethyl; a lower alkoxyethyl group, e.g., methoxyethyl, ethoxyethyl, isobutoxyethyl; a lower aliphatic acyloxyethyl group, e.g., acetoxyethyl, propionyloxyethyl, butyryloxyethyl, pivaloyloxyethyl; a 1-lower alkoxyethoxycarbonyloxyethyl group, e.g., 1-methoxyethoxycarbonyloxyethyl, 1-ethoxyethoxycarbonyloxyethyl; an aralkyl group, e.g., p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl a benzhydryl group and a phthalidyl group.

When X is a  $(C_1-C_3)$ alkyl-substituted or unsubstituted methylene group as represented by the formula (1), the  $(C_1-C_3)$ alkyl group includes, for example, methyl, ethyl, n-propyl,

When Y is an amino group represented by the formula (2),  $R_5$  and  $R_6$  may be the same or different from each other. In the definition of  $R_5$  and  $R_6$ , the alkyl group having 1 to 5 carbon atoms includes e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl; the alkenyl group having 3 to 4 carbon atoms includes, for

example, propenyl, butenyl; the aralkyl group having 1 to 3 carbon atoms in its alkyl moiety includes, for example, a phenyl group, a substituted phenyl group, a pyridyl group and a (C<sub>1</sub>-C<sub>3</sub>) alkyl group substituted with a substituted pyridyl group, such as benzyl, substituted benzyl, phenethyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl; the substituted alkyl group having 1 to 5 carbon atoms includes, for example, a straight chain or branched chain alkyl group, e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, etc., which is substituted with a hydroxyl group, a di-(C<sub>1</sub>-C<sub>3</sub>) alkylamino group, a carbamoyl group, a mono- or di-(C<sub>1</sub>-C<sub>3</sub>) alkyl-substituted aminocarbonyl group, a protected or unprotected carboxyl group or a like substituent; and the pyridyl group includes 2-pyridyl, 3-pyridyl and 4-pyridyl groups.

In cases where R<sub>5</sub> and R<sub>6</sub> jointly represent an alkylene chain or an alkylene chain via an oxygen atom, a sulfur atom or a (C<sub>1</sub>-C<sub>3</sub>) alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a substituted or unsubstituted 3- to 7-membered cyclic amino group which may contain double bond(s) in its ring, the cyclic amino group includes, for example, a saturated cyclic amino group, e.g., an aziridino group, an azetidino group, a pyrrolidino group, a piperidino

group, etc.; an unsaturated cyclic amino group, e.g.,  
a pyrrolyl group, a 3-pyrrolinyl group; . . . and a cyclic  
amino group having an oxygen atom, a sulfur atom or an  
alkyl-substituted nitrogen atom in its ring, e.g., a  
5 morpholino group, a thiomorpholino group, an N-methyl-  
piperazino group; The substituents for these cyclic  
amino groups include, for example, an alkyl group having  
1 to 3 carbon atoms, a carbamoyl group, a mono- or di-  
(C<sub>1</sub>-C<sub>3</sub>)alkyl-substituted aminocarbonyl group, a hydroxyl  
10 group, etc.

When Y is represented by the formula (3), the  
guanidyl group unsubstituted or substituted with a (C<sub>1</sub>-C<sub>3</sub>)  
alkyl group includes a guanidyl group and a guanidyl group  
substituted with one to four alkyl groups, e.g., methyl,  
15 ethyl, n-propyl, isopropyl, . . . , such as an N,N'-tetra-  
methylguanidyl group.


The hydrazino group for Y includes, for example,  
a hydrazino group and a hydrazino group substituted with  
one to three alkyl groups, e.g., methyl, ethyl, n-propyl,  
20 isopropyl, . . . such as 2',2'-dimethylhydrazino, trimethyl-  
hydrazino.

In cases where Y is represented by the formula  
(4), R<sub>8</sub> is a hydrogen atom, a protecting group commonly  
employed for protection of a hydroxyl group or a lower  
25 alkyl group, e.g., methyl, ethyl, n-propyl; . . .

Of the compounds of the above-described

formula (I), the carboxylic acid compounds wherein the group as represented by  $-COOR_3$  or  $-COY$  is a carboxyl group can be converted into their pharmacologically acceptable salts, if desired. Such salts include those formed with inorganic metals, such as lithium, sodium, potassium, calcium, magnesium, etc. and those formed with ammonium, such as ammonium, cyclohexylammonium, diisopropylammonium, triethylammonium, etc., with a sodium salt and a potassium salt being preferred.

The preferred compounds of the formula (I) are those wherein  $R_1$  is a hydrogen atom or a 1-hydroxyethyl group;  $R_2$  and  $R_3$  are both hydrogen atoms; and Y is a group represented by the formula (2-a):



wherein  $R_{5-a}$  and  $R_{6-a}$  each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 3 to 4 carbon atoms, an aralkyl group having 1 to 3 carbon atoms in its alkyl moiety, an alkyl group having 1 to 5 carbon atoms which is substituted with a hydroxyl group, a di-( $C_1-C_3$ )alkylamino group, a carbamoyl group, a mono- or di-( $C_1-C_3$ )alkyl-substituted aminocarbonyl group, a carboxyl group, etc., or a pyridyl




group, or  $R_{5-a}$  and  $R_{6-a}$  jointly represent an alkylene chain or an alkylene chain containing an oxygen atom, a sulfur atom or a  $(C_1-C_3)$ alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a substituted or unsubstituted 3- to 7-membered cyclic amino group which may contain double bond(s) in the ring thereof, wherein the substituent for the cyclic amino group includes a  $(C_1-C_3)$ alkyl group, a carbamoyl group, a carboxyl group, a mono- or di- $(C_1-C_3)$ alkyl-substituted aminocarbonyl group, a hydroxyl group, etc.; an unsubstituted or  $(C_1-C_3)$ alkyl-substituted guanidyl group; a hydroxyl group; an alkoxy group having 1 to 3 carbon atoms; an unsubstituted or  $(C_1-C_3)$ alkyl-substituted hydrazino group; or a group represented by the formula (4-a):



(4-a)

wherein  $R_{8-a}$  represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms.

The more preferred compounds of the formula (I) are those wherein  $R_1$  is a 1-hydroxyethyl group;  $R_2$  and  $R_3$  are both hydrogen atoms; and Y is a group represented by the formula (2-b):



(2-b)

wherein  $R_{5-b}$  and  $R_{6-b}$  each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 3 to 4 carbon atoms, an aralkyl group having 1 to 3 carbon atoms in its alkyl moiety, an alkyl group having 1 to 5 carbon atoms which is substituted with a hydroxyl group, a di- $(C_1-C_3)$ alkylamino group, a carbamoyl group, a mono- or di- $(C_1-C_3)$ alkyl-substituted aminocarbonyl group, a carboxyl group, etc., or a pyridyl group, or  $R_{5-b}$  and  $R_{6-b}$  jointly represents an alkylene chain or alkylene chain via an oxygen atom, a sulfur atom or a  $(C_1-C_3)$ alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a substituted or unsubstituted 3- to 7- membered cyclic amino group which may contain double bond(s) in its ring, wherein the substituent for the cyclic amino group includes an alkyl group having 1 to 3 carbon atoms, a carbamoyl group, a hydroxyl group, etc.; an unsubstituted or  $(C_1-C_3)$ alkyl-substituted guanidyl group; a hydroxyl group; an alkoxy group having 1 to 3 carbon atoms, preferably a methoxy group; an unsubstituted or  $(C_1-C_3)$ alkyl-substituted hydrazino group; or a group represented by the formula (4-a):



(4-a)

wherein  $R_{8-a}$  has the same meaning as defined above.

The most preferred compounds of the formula  
(I) are those wherein  $R_1$  is a 1-hydroxyethyl group;  
 $R_2$  and  $R_3$  are both hydrogen atoms; and Y is a group  
5 represented by the formula (2-c):



wherein  $R_{5-c}$  and  $R_{6-c}$  have one of the following meanings:

- 10 (1)  $R_{5-c}$  represents an alkyl group having 1 to 5 carbon atoms which may be substituted with a carbamoyl group, a mono- or di-( $C_1-C_3$ )alkylamino-carbonyl group, a hydroxyl group, etc., or a pyridyl group, and  $R_{6-c}$  represents a hydrogen atom or has the same meaning as described for  $R_{5-c}$ ;
- 15 (2)  $R_{5-c}$  and  $R_{6-c}$  are directly taken together to represent an alkylene chain to form, together with the adjacent nitrogen atom, a 4- to 6-membered saturated cyclic amino group or a 5- to 6-membered unsaturated cyclic amino group having double bond(s)  
20 in its ring, such as a pyrrolinyl group, or the same saturated or unsaturated cyclic amino group as described above but having a substituent on its ring, such as a carbamoyl group, a hydroxyl

group, etc.; and

- (3)  $R_{5-C}$  and  $R_{6-C}$  jointly represent an alkylene chain via an oxygen atom or a  $(C_1-C_3)$ alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a 6-membered cyclic amino group.

Preferred examples of X, if positively enumerated, can include a methyl-substituted or unsubstituted methylene group represented by the formula (1-a):



wherein  $R_{4-a}$  represents a hydrogen atom or a methyl group,

with a group  $\begin{array}{c} CH_3 \\ | \\ -C- \\ | \\ H \end{array}$  being particularly preferred.


The  $\beta$ -lactam compounds represented by the formula (I) according to the present invention are

novel compounds which are carbapenem (i.e., 1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid) derivatives or penem (i.e., 1-azabicyclo[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylic acid) derivatives.

5 A process for producing the compounds of the formula (I) according to the present invention will be described below.

Of the  $\beta$ -lactam compounds of the formula (I), compounds represented by the formula (IV):

10




wherein  $R_1$ ,  $R_2$  and  $X$  are as defined above;  $R_9$  represents a protecting group for a carboxyl group; and  $Y'$  represents the group as represented by the foresaid formula (2), the group as represented by the aforesaid formula (3), a protected hydroxyl group, an alkoxy group having 1 to 3 carbon atoms, an unsubstituted or (C<sub>1</sub>-C<sub>3</sub>)alkyl-substituted hydrazino group or a group represented by the formula (4'):

15




wherein  $R_8'$  represents a protecting group for a hydroxyl group or an alkyl group having 1 to 3 carbon atoms,

can be prepared by reacting a  $\beta$ -lactam derivative  
 5 represented by the formula (II):



wherein  $R_1$ , X and  $R_9$  are as defined above, and Z represents a reactive ester group of an alcohol or a substituted or unsubstituted lower alkylsulfinyl group,  
 10 with a mercaptan derivative represented by the formula (III):



wherein  $R_2$  and  $Y'$  are as defined above,  
 in an inert solvent in the presence of a base.

15

The term "reactive ester group of an alcohol"

herein used means a group derived from a substituted or unsubstituted arylsulfonate, lower alkanesulfonate, halogeno-lower alkanesulfonate or diarylphosphoric acid ester or a halide, i.e., an ester with a hydrogen halide, of the alcohol represented by the formula (II).

5 The substituted or unsubstituted arylsulfonate includes, for example, a benzenesulfonate, a p-toluenesulfonate, a p-nitrobenzenesulfonate, a p-bromobenzenesulfonate, etc. The lower alkanesulfonate includes, for example, a methanesulfonate, an ethanesulfonate. The

10 halogeno-lower alkanesulfonate includes, for example, a trifluoromethanesulfonate. The diarylphosphoric acid ester includes, for example, a diphenylphosphoric acid ester, etc. The halide includes, for example, a

15 chloride, a bromide, an iodide, etc. Of these reactive esters of an alcohol, preferred examples are a p-toluenesulfonate, a methanesulfonate and a diphenylphosphoric acid ester.

Further, in the substituted or unsubstituted

20 lower alkylsulfinyl group, the lower alkyl group preferably includes a straight chain or branched chain alkyl group having 1 to 4 carbon atoms. The substituent for the substituted lower alkyl group can include a hydroxyl group, a lower alkoxy group having 1 to 4

25 carbon atoms, a lower alkoxycarbonyloxy group having

2 to 5 carbon atoms, a lower alkanoyloxy group having  
2 to 5 carbon atoms, an amino group, a mono- or di-  
lower alkylamino group, a lower alkanoylamino group  
having 2 to 5 carbon atoms, a lower alkoxy carbonylamino  
5 group having 2 to 5 carbon atoms, an aralkyloxy carbonyl-  
oxy group, an aralkyloxy carbonylamino group, etc.

The protecting group for a carboxyl group as  
represented by  $R_9$  corresponds to the protecting group  
as represented by  $R_3$ , and the same preferred groups as  
10 enumerated for  $R_3$  can also be applied to  $R_9$ .

Examples of the inert solvent which can  
be used in the above-described reaction are dioxane,  
tetrahydrofuran, dimethylformamide, dimethyl sulfoxide,  
acetonitrile, hexamethylphosphoramide and mixtures  
15 thereof, with acetonitrile and dimethylformamide being  
preferred.

The base also used in the reaction includes  
various organic or inorganic bases, such as sodium  
carbonate, potassium carbonate, sodium hydride, potassium  
20 hydride, potassium t-butoxide, pyridine, various lutidines,  
4-dimethylaminopyridine, triethylamine, diisopropylethyl-  
amine and the like, with the organic bases, e.g., diiso-  
propylethylamine, etc., being preferred.

The amount of the base to be used should be  
25 enough for the reaction to sufficiently proceed and



usually ranges from 1 to 2 equivalents per mole of the mercaptan derivative of the formula (III).

The mercaptan derivative (III) is used in an amount enough for the reaction to sufficiently proceed. It may be used in a large excess but usually in an amount of from 1 to 2 equivalents based on the compound of the formula (II).

The reaction can be carried out at a temperature ranging from about  $-78^{\circ}\text{C}$  to  $60^{\circ}\text{C}$ , preferably from  $-40^{\circ}\text{C}$  to  $40^{\circ}\text{C}$ .

After completion of the reaction, the reaction product can be isolated by usual organochemical means.

Then, the thus obtained compound represented by the formula (IV) can be subjected, if necessary, to a reaction for removal of the hydroxyl-protecting group when  $\text{R}_1$  is a protected hydroxyl group, a reaction for removal of the amino-protecting group, a reaction for removal of the carboxyl-protecting group  $\text{R}_9$ , a reaction for removal of the protecting group on  $\text{Y}'$ , or an appropriate combination thereof, thereby to obtain the  $\beta$ -lactam compound represented by the formula (I).


The reactions for removal of the protecting groups can be carried out by generally known methods selected depending on the type of the protecting groups.

For example, those compounds of the formula (IV) wherein the hydroxyl-protecting group and/or the amino-protecting group in  $R_2$  is/are a halogeno-alkoxycarbonyl group(s) or an aralkyloxycarbonyl group(s), and those compounds wherein the carboxyl-protecting group is a halogenoalkyl group, an aralkyl group or a benzhydryl group can be subjected to an appropriate reduction reaction to remove these protecting groups. Such reduction is preferably carried out by using an organic solvent, such as acetic acid, tetrahydrofuran, methanol, etc., and zinc in case when the protecting group to be removed is a halogenoalkoxycarbonyl group or a halogenoalkyl group, or by catalytic reduction using a catalyst, such as platinum or palladium-on-carbon, in case when the protecting group to be removed is an aralkyloxycarbonyl group, an aralkyl group or a benzhydryl group. Solvents to be used in the catalytic reduction suitably include organic solvents, such as lower alcohols, e.g., methanol, ethanol, etc.; ethers, e.g., tetrahydrofuran, dioxane, etc.; and acetic acid, or mixed solvents of these organic solvents and water or buffer solutions, such as phosphoric acid, morpholinopropanesulfonic acid, etc. The reaction can be conducted at a temperature of from about 0°C to 100°C, preferably 0°C to 40°C, in a hydrogen atmosphere under

atmospheric pressure or under pressurized conditions.


In particular, when the protecting group to be removed is an o-nitrobenzyl group or an o-nitrobenzyloxycarbonyl group, these groups can also be removed by photo reaction.

In the compounds according to the present invention, the 5- and 6-positions of the compounds of the above-described formula (I), the 8-position of the compounds represented by the formula (V):



wherein  $R_2$ ,  $R_3$ ,  $X$  and  $Y$  are as defined above, and  $R_{10}$  represents a hydrogen atom or a protecting group for a hydroxyl group,

the 4-position of the compounds represented by the formula (VI):



wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and Y are as defined above, and  $R_4$  is an alkyl group, and the 2'- and 4'-positions in the 2-side chain of the compounds of the formulae (I), (V) and (VI) are all asymmetric carbons to form isomers. Therefore, the compounds represented by these formulae include optical isomers and steric isomers ascribed to these asymmetric carbon atoms. Although all of these isomers are represented by a respective single formula for the sake of convenience, the scope of the present invention is not limited by such a single formula.

However, preferred isomers can include those having an R-configuration at the 5-positioned carbon atom, similarly to thienamycin, i.e., the (5R,6S)- or (5R,6R)-compounds. With respect to the 8-positioned carbon atom of the formula (V), those having an R-configuration are preferred. Further, with respect to the 4-position of the formula (VI), those wherein the lower alkyl group as represented by  $R_4$  is in a R-configuration (i.e., (4R)-compounds) are preferred.


In addition, the 2'-substituted pyrrolidin-4'-ylthio group forms four isomers, of which the (2'S,4'S)- and (2'R,4'R)-compounds are preferred.

Particularly preferred compounds include those compounds of the formula (I) having a (5R,6S,2'S,4'S)-

configuration, those compounds of the formula (V) having a (5R,6S,8R,2'S,4'S)-configuration, and those compounds of the formula (VI), wherein  $R_1$  is a 1-hydroxyethyl type substituent and  $R_4$  is a lower alkyl group, having  
 5 a (4R,5R,6S,8R,2'S,4'S)-configuration.

The isomers having the above-described steric configurations can be obtained by using the starting compounds of the formula (II) and/or (III) having the corresponding configurations.

10 The starting compounds (II) can be prepared according to various known methods. For example, the compounds represented by the formula (VII):




(VII)

wherein  $R_4$ ,  $R_9$  and  $R_{10}$  are as defined above, and  $Z_0$   
 15 represents a reactive ester group of an alcohol, and also wherein  $R_4$  is a hydrogen atom are known per se in (1) Japanese Patent Application OPI (Open to Public Inspection) No. 27169/80, (2) J. Am. Chem. Soc., Vol. 103, 6765-6767 (1981) and (3) J. Chem. Soc.,  
 20 Perkin I, 964-968 (1981), etc., and the compounds (VII) can be obtained according to the methods described in

the above-described literatures (1) to (3).

Further, the compounds (VII) can also be synthesized in accordance with the methods described in the above-described literatures (1) to (3), etc.

5 starting with compounds represented by the formula (a):




(a)

wherein  $R_{10}$  is as defined above, and Ac represents an acetyl group,

which can be obtained by the method described in  
10 Tetrahedron Letters, 2293-2296 (1982) or the method described in EPC Publication No. 70204.


Furthermore, the compounds (VII) can also be obtained by subjecting a compound represented by the formula (b):



(b)

wherein DAM represents a di-p-anisylmethyl group,

which is obtained by the method disclosed in EPC  
Publication No. 70204 to a carbon-increasing reaction  
such as Arndt-Einstert reaction and the like and then  
to an oxymercuration reaction and the like according  
5 to the method of EPC Publication No. 70204, thereby  
converting the ethenyl group into a 1-hydroxyethyl  
group, subjecting the resulting product, if necessary,  
to an appropriate combination of a reaction for  
protecting or deprotecting the carboxyl group and a  
10 reaction for protecting the hydroxyl group to obtain a  
compound represented by the formula (c):




wherein  $R_{10}$  and DAM are as defined above,  
and then obtaining the compound (VII) from the compound  
15 (c) in accordance with the method described in Japanese  
Patent Application OPI No. 167964/82.

The DAM group on the nitrogen atom in the  
compound (c) can be removed by reacting with ceric  
ammonium nitrate in an inert solvent such as aceto-  
20 nitrile-water at 10 to 30°C. In this case, this reaction

may be combined with a reaction for protecting or deprotecting the carboxyl group and/or a reaction for protecting the hydroxyl group, if necessary.

Further, the compound of the formula (VII) wherein  $R_4$  is an alkyl group can be prepared by, for example, the known method as disclosed in Japanese Patent Application OPI No. 26887/83 or analogous methods thereof.


Compounds of the formula (VIII):



wherein  $R_{10}$  is as defined above. and  $R_4^0$  represents an alkyl group having 1 to 3 carbon atoms, which can be used as a starting material for preparing the compound (VII) wherein  $R_4$  is an alkyl group, can be produced, for example, according to the following reaction scheme:


15





wherein  $R_4^0$  is as defined above;  $R_{11}$  represents a protecting group for a carboxyl group; and TBDMS represents a t-butyldimethylsilyl group.

5                      The compounds of the formulae (e) and (f) can be obtained as an isomeric mixture by a method described in Japanese Patent Application OPI No. 73656/80 which comprises reacting (3R,4R)-4-acetoxy-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-2-azetidinone  
 10 of the formula (d) disclosed in Chem. Pharm. Bull., Vol. 29, 2899-2909 (1981) with a halogenofatty acid ester represented by the formula:




wherein  $R_4^0$  and  $R_{11}$  are as defined above, and  $X'$  represents a halogen atom,


in a solvent, such as an ether (e.g., tetrahydrofuran, dioxane, diethyl ether, etc.), an aromatic hydrocarbon (e.g., benzene, toluene, etc.), and the like, or a mixed solvent of these solvents and hexane in the presence of diethylaluminium chloride and zinc.

Separation and purification of the isomers (e) and (f) can be carried out by silica gel column chromatography.

The compounds (e) and (f) can be led to the compound (VIII) by appropriately combining reactions for protecting or deprotecting the hydroxyl group, the carboxyl group or the nitrogen atom.

One example for the production of the starting compound (VII) will be illustrated in the following reaction scheme:





wherein  $R_4$ ,  $R_9$  and  $R_{10}$  are as defined above;  $R_{10}^0$  represents a protecting group for a hydroxyl group; and Ph represents a phenyl group.

More specifically, the compound (g) obtainable by the aforesaid methods can be led to the compound (h) through the reaction described in Japanese Patent Application OPI No. 167964/82 or Heterocycles, Vol. 14, 1305-1306 (1980).

The compound (h) is then reacted with a diazonizing agent, e.g., carboxybenzenesulfonazide, in the presence of a base to obtain the compound (i) as disclosed in Tetrahedron Letters, 31-34 (1980).

The compound (i) is then subjected to cyclization


in the presence of a metal salt catalyst, e.g., dirhodium tetrakisacetate, or by photo reaction to obtain the compound (j).

Finally, the compound (j) is reacted with diphenyl-  
5 phosphoryl chloride in an inert solvent in the presence of a base such as diisopropyl ethyl amine, 4-dimethylamino-pyridine, etc. to obtain the compound of the formula (VII-a).

In general, the starting compound (VII-a) as prepared from the compound (j) is subsequently subject-  
10 ed to the reaction with various mercaptans without being isolated to produce carbapenem derivatives, but the starting compound (VII-a) may be once isolated from the reaction mixture and then reacted with the mercaptan derivative (III) to obtain the desired compound of the  
15 formula (IV).


Optically active reactive esters, for example, the compound (VII-a), can be obtained in the same manner as described above but starting with the  $\beta$ -lactam  
20 derivative (g) having the corresponding steric configuration.

Further, of the above-described compounds of the formula (II), the compounds, for example, of the compound (IX):



wherein  $R_1$  and  $R_9$  are as defined above, and  $R_{12}$  represents a substituted or unsubstituted lower alkyl group,

5 can be prepared by subjecting a compound of the formula (X):










wherein  $R_1$ ,  $R_9$  and  $R_{12}$  are as defined above, to S-oxidation using a mild oxidizing agent. The mild oxidizing agent includes perbenzoic acid, m-chloro-perbenzoic acid, hydrogen peroxide, selenium dioxide, 10 sodium m-periodate and the like, with substituted perbenzoic acids, e.g., m-chloroperbenzoic acid, etc., being preferred.





The starting compound represented by the

formula (X) can be prepared by various methods already reported, for example, the methods as disclosed in Japanese Patent Applications OPI Nos. 9034/80, 105686/80 and 81591/81.

5 On the other hand, the starting mercaptan derivative of the formula (III) can be prepared by various methods. For example, mercaptan derivatives (IIIa), (IIIb) and (IIIc) having a 2'S-configuration can be obtained from trans-4-hydroxy-L-proline (i) in accordance with the reaction scheme shown below:









In the above formulae,  $R_5$ ,  $R_6$  and  $R_{11}$  are as defined above;  $R_{13}$  represents a protecting group for an amino group; and  $R_{14}$  represents a protecting group for a thiol group.

5     Step A:

          The reaction can easily be accomplished by various known methods generally employed for protecting an amino group of amino acids, for example, a method comprising reacting with an arylmethyloxycarbonyl chloride, etc. in the presence of a base, a method comprising using an S-acyl-4,6-dimethyl-2-mercaptopyrimidine, etc., and the like.

Step B:

          The reaction can be carried out by various methods for obtaining esters from carboxylic acids, for example, by reacting the carboxylic acid (ii) with various alkyl halides or aralkyl halides, etc. in the presence of a base.

Step C:

20       The reaction can be accomplished by various known methods for converting a hydroxyl group into a protected thiol group, for example, by a method comprising converting the carboxylic acid ester (iii) into an active ester of a hydroxyl group and then reacting with various thionizing reagents, e.g., thioacetic

25

acid, thiobenzoic acid, tritylmercaptan, etc., in the presence of a base.


This step may also be conducted by reacting the alcohol derivative with a thionizing reagent, e.g.,  
 5 thioacetic acid, etc., in an inert solvent, e.g., tetrahydrofuran, etc., in the presence of triphenylphosphine and diethyl azodicarboxylate.

Step D:

This step can be carried out by various  
 10 known methods for converting an ester group into a carboxyl group, for example, alkali-hydrolysis, a method of using trifluoroacetic acid, hydrobromic acid, etc., or a reductive method of using zinc.

Step E:

15 The reaction can be achieved by various known methods for converting a carboxyl group to an amido group, for example, by a method comprising reacting with a halogenating agent, an acylating agent, etc. to form an active ester derivative and then treating  
 20 the resulting ester with an amine represented by the formula:



wherein  $R_5$  and  $R_6$  are as defined above.

Step F:

The thiol-protecting group can be removed by various known methods for deprotection. For example, an acyl group as the thiol-protecting group can be removed by alkali-hydrolysis and the like.

5

Step G:

The reaction can be accomplished by various known oxidation methods for converting a hydroxyl group into a carbonyl group, for example, an oxidation reaction using chromic acid-sulfuric acid, etc. in acetone.

10

Step H:

The step can be conducted by various known reduction reactions for converting a carbonyl group to a hydroxyl group. For example, treatment with sodium borohydride, etc. gives a mixture of the compound (iii) and the compound (ix) having different steric configurations at the hydroxyl group. The production proportion of (iii) and (ix) varies depending on reaction conditions, but each compound can be isolated as a single compound by purification procedures, such as recrystallization, chromatography and the like.

15

20

Isomerization of the 4-hydroxyl group can be accomplished through the above-described steps G and H, and may also be achieved through hereinafter described steps I and J.

25

Steps I & J:

The alcohol derivative is reacted with formic acid in an inert solvent, e.g., tetrahydrofuran, etc., in the presence of triphenylphosphine and diethyl azodicarboxylate to form a formyloxy derivative (xiii), which is then subjected to alkali-hydrolysis, etc. to remove the formyl group.

Step K:

This step can be conducted by commonly employed various known methods for deprotecting amino groups, for example, a method of using an acid, e.g., trifluoroacetic acid, hydrobromic acid, etc., a reducing method of using zinc, lithium-liquid ammonia, etc., or a catalytically reducing method.

The starting mercaptan derivatives (III) to be used for the production of the  $\beta$ -lactam compounds (I) wherein Y is a protected or unprotected hydroxyl group or an alkoxy group having 1 to 3 carbon atoms can be obtained by subjecting the compound (iv) or (x) to Step F.

The 2'R-mercaptan (III) can be prepared by using cis-4-hydroxy-D-proline as a starting compound in accordance with the above-described method for producing 2'S-compounds, i.e., by combining various reactions described in the production of the 2'S-compounds.

Of the novel  $\beta$ -lactam compounds represented by the formula (I) according to the present invention, those compounds in which  $R_1$ ,  $R_2$  and  $R_3$  are all hydrogen atoms exhibit excellent antimicrobial activity against a wide variety of disease-causing bacteria including Gram positive bacteria, such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus faecalis, etc., and Gram negative bacteria, such as Escherichia coli, Proteus mirabilis, Serratia marcescens, Pseudomonas aeruginosa, etc., and are useful, therefore, as antimicrobial agents. Further, these compounds have a characteristic of exhibiting excellent antimicrobial activity against  $\beta$ -lactamase-producing strains. Other compounds according to the present invention are important intermediates for synthesizing the above-mentioned compounds having antimicrobial activity.

In addition, the compounds according to the present invention are also characterized in general by their high physiochemical stability and excellent water solubility, although varying depending on the respective compound.

The compounds of the present invention can be used as antimicrobial agents for treating bacteria-caused infectious diseases in the form of oral preparations,

such as tablets, capsules, powders, syrups, etc. or non-oral preparations, such as intravenous injections, intramuscular injections, rectal preparations, etc.

5 The dosage of the antimicrobial agent varies depending upon the symptoms, ages, body weights, dosage forms, times of doses and the like, but usually ranges from about 100 mg to 3,000 mg per day in a single dose or several divided doses for adults. The above dose level can be increased or decreased according to  
10 necessity.

Besides, the antimicrobial agent of the present invention can be administered, if necessary, in combination with dehydrodipeptidase-inhibitors, e.g., sodium Z-7-(L-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclo-  
15 propanecarboxyamido)-2-heptenoate, etc. (a series of compounds disclosed in Japanese Patent Application OPI No. 81518/81).

The present invention will now be illustrated in greater detail with reference to the following  
20 Reference Examples and Examples, which are given only for illustration.

"Nujol" is a paraffinic solvent.


In Reference Examples and Examples, the following abbreviations are used:

25 DAM: Di-(p-anisyl)methyl group

TBDMS: t-Butyldimethylsilyl group

PNZ: p-Nitrobenzyloxycarbonyl group  
PMZ: p-Methoxybenzyloxycarbonyl group  
PMB: p-Methoxybenzyl group  
PNB: p-Nitrobenzyl group  
5 Ph : Phenyl group  
Ac : Acetyl group  
Ms : Methanesulfonyl group  
tBu: t-Butyl group  
Me : Methyl group  
10 Et : Ethyl group

Reference Example 1-1



6.55 g of trans-4-hydroxy-L-proline and 7.5 ml  
of triethylamine were dissolved in 15 ml of water, and a  
15 solution of 15.95 g of S-p-nitrobenzyloxycarbonyl-4,6-  
dimethyl-2-mercaptopyrimidine in 35 ml of dioxane was  
added thereto dropwise. The resulting mixture was stirr-  
ed at room temperature for 1.5 hours and allowed to stand  
overnight. To the reaction mixture was added 30 ml of a  
20 2N sodium hydroxide aqueous solution under ice-cooling,  
and the resulting mixture was extracted with diethyl ether.  
The ethereal layer was washed with 20 ml of a 1N sodium

hydroxide aqueous solution and combined with the alkaline aqueous layer. The combined mixture was made acidic with 100 ml of a 2N hydrochloric acid aqueous solution and extracted with ethyl acetate.


5 The ethyl acetate layer was washed with a 2N aqueous solution of hydrochloric acid, dried over sodium sulfate and distilled off to remove the solvent. The resulting crude crystals were washed with warm ethyl acetate to obtain trans-1-(p-nitrobenzyloxycarbonyl)-  
10 4-hydroxy-L-proline.

Melting Point: 134.3-135.5°C

IR<sup>Nujol</sup><sub>max</sub> (cm<sup>-1</sup>): 3300 (br.), 1738, 1660, 1605,  
1520, 1340, 1205, 1172, 1070,  
965

15

Reference Example 1-2



15.0 g of trans-1-(p-nitrobenzyloxycarbonyl)-  
4-hydroxy-L-proline and 13.5 ml of triethylamine were  
dissolved in 150 ml of dried dimethylformamide, and  
20 12.66 ml of p-methoxybenzyl chloride was added dropwise  
to the solution under a nitrogen stream, followed by




stirring at 70°C for 10 hours. The reaction mixture was diluted with 500 ml of ethyl acetate, washed with water, dried over sodium sulfate and distilled off to remove the solvent. Recrystallization of the residue from diethyl ether gave trans-1-(p-nitrobenzyloxy-carbonyl)-4-hydroxy-L-proline p-methoxybenzyl ester.

Melting Point: 83-85°C

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 3430, 1735, 1705, 1510, 1340, 1245, 1160

Reference Example 1-3



8.6 g of trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-proline-p-methoxybenzyl ester and 7.86 g of triphenylphosphine were dissolved in 20 ml of dried tetrahydrofuran. To the resulting solution was added dropwise a solution of 5.22 g of diethyl azodicarboxylate in 5 ml of dried tetrahydrofuran under ice-cooling in a nitrogen stream, followed by stirring for 30 minutes at that temperature. Thereafter, 2.28 g of thioacetic acid was added thereto dropwise, and the mixture was stirred for 1 hour under ice-cooling and then at room temperature


for 3 hours, followed by concentration. The residue was purified by silica gel column chromatography to obtain cis-1-(p-nitrobenzyloxycarbonyl)-4-acetylthio-L-proline p-methoxybenzyl ester.

5  $IR_{\max}^{\text{neat}}$  ( $\text{cm}^{-1}$ ): 1740 (sh.), 1715, 1520, 1405, 1348, 1120

NMR  $\delta$  ( $\text{CDCl}_3$ ): 2.31 (3H, s), 3.79 (3H, s), 5.10 (2H, s), 5.24 (2H, s), 7.49 (2H, d,  $J=9.0\text{Hz}$ ), 8.18 (2H, d,  $J=9.0\text{Hz}$ )ppm

10

Reference Example 1-4




9.76 g of cis-1-(p-nitrobenzyloxycarbonyl)-4-acetylthio-L-proline p-methoxybenzyl ester and 4.32 g of anisole were stirred together with 35 ml of trifluoroacetic acid at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain cis-1-(p-nitrobenzyloxycarbonyl)-4-acetylthio-L-proline.

20

Melting Point : 107-109°C

$IR_{\max}^{\text{Nujol}}$  ( $\text{cm}^{-1}$ ): 1725, 1685, 1660 (sh.), 1340,

1180, 1110

Reference Example 1-5

180 mg of cis-1-(p-nitrobenzyloxycarbonyl)-  
5 4-acetylthio-L-proline was dissolved in 2 ml of dried  
tetrahydrofuran, and 48 mg of dimethylamine hydro-  
chloride, 78 mg of N,N-dimethylaminopyridine and 152 mg  
of dicyclohexylcarbodiimide were successively added  
thereto, followed by stirring overnight. After any  
10 insoluble matter was removed by filtration, the filtrate  
was diluted with ethyl acetate, washed successively with  
dilute hydrochloric acid and water, dried over sodium  
sulfate and distilled off to remove the solvent. The  
residue was purified by silica gel chromatography to  
15 obtain (2S,4S)-cis-1-(p-nitrobenzyloxycarbonyl)-2-  
dimethylcarbamoyl-4-acetylthiopyrrolidine.

The above prepared compound could also be  
obtained by the following method:

200 mg of the same starting carboxylic acid  
20 was dissolved in 1.8 ml of dried methylene chloride,  
and one drop of dimethylformamide was added thereto.


0.12 ml of oxalyl chloride was then added dropwise thereto under ice-cooling, followed by stirring at room temperature for 1 hour. The solvent was removed by distillation, and the residue was thoroughly dried in vacuo and dissolved in 1 ml of dried tetrahydrofuran. Under ice-cooling, 1.2 ml of a 1M solution of dimethylamine in tetrahydrofuran was added to the reaction mixture, followed by stirring at that temperature for 15 minutes. To the reaction mixture was added ice-water, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with dilute hydrochloric acid and water, dried over sodium sulfate and distilled off to remove the solvent.

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1705, 1650, 1515, 1400, 1340, 1105

NMR  $\delta$  (CDCl<sub>3</sub>): 2.32 (3H, s), 2.97 (3H, s), 3.11 (3H, s), 5.21 (2H, s), 8.18 (2H, d, J=8.5Hz) ppm

[ $\alpha$ ]<sub>D</sub><sup>30</sup> +5.21° (c=0.379, acetone)

Reference Example 1-6




277 mg of (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-hydroxycarbonyl-4-acetylthiopyridine was dissolved in 1.5 ml of dried methylene chloride, and 0.15 ml of oxalyl chloride and a catalytic amount of dimethylform-  
amide were added thereto, followed by stirring at room temperature for 1.5 hours. The reaction mixture was distilled off to remove the solvent, and dried benzene was added to the residue. The benzene was then distilled off to remove any remaining oxalyl chloride.

Separately, 51 mg of pyrrole was dissolved in 2 ml of dried tetrahydrofuran, and 0.47 ml of a 1.60 mmol/ml solution of n-butyl lithium in hexane was added thereto in a nitrogen stream under ice-cooling, followed by stirring at that temperature for 40 minutes. The resulting mixture was then added in a nitrogen stream under ice-cooling to a solution of the above-described reaction residue dissolved in 2 ml of dried tetrahydrofuran, followed by stirring for 10 minutes. The resulting reaction mixture was diluted with methylene chloride, washed with water, dried over sodium sulfate and distilled off to remove the solvent. The residue was purified by silica gel thin layer chromatography to obtain (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-(1-pyrrolyl)carbonyl-4-acetylthiopyrrolidine.

IR  $\nu_{\text{max}}^{\text{CHCl}_3}$  ( $\text{cm}^{-1}$ ): 1710, 1525, 1345, 1278, 1120

NMR  $\delta$  ( $\text{CDCl}_3$ ): 2.33 (3H, s), 5.23 (2H, s),  
 6.35 (2H, d,  $J=2\text{Hz}$ ), 7.51  
 (2H, d,  $J=9\text{Hz}$ ) ppm

Reference Example 1-7



368 mg of (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-hydroxycarbonyl-4-acetylthiopyrrolidine was dissolved in 3 ml of dried methylene chloride, and 0.3 ml of oxalyl chloride and a catalytic amount of dimethylformamide were added thereto, followed by stirring at room temperature for 1.5 hours. The reaction mixture was distilled off to remove the solvent, and to the residue was added dried benzene. The benzene was then distilled off to remove any remaining oxalyl chloride. Separately, 128 mg of 4-carbamoylpiperidine was dissolved in 3 ml of dried tetrahydrofuran, and 0.25 ml of bistrimethylsilylacetamide was added to the solution, followed by stirring for 3 hours in a nitrogen stream. Then, 101 mg of triethylamine was added thereto, and to the resulting mixture was added in a nitrogen stream under ice-cooling a solution of the above-obtained reaction residue dissolved

10

15


20

in 3 ml of dried tetrahydrofuran, followed by stirring for 15 minutes under ice-cooling. Methylene chloride was added to the resulting reaction mixture. The mixture was washed successively with a sodium chloride aqueous solution, dilute hydrochloric acid, a sodium chloride aqueous solution, a sodium bicarbonate aqueous solution and a sodium chloride aqueous solution, dried over sodium sulfate and distilled off to remove the solvent. The residue was purified by silica gel thin layer chromatography to obtain (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-(4-carbamoylpiperidinyl)carbonyl-4-acetylthiopyrrolidine.

IR  $\nu_{\text{max}}$   $\text{CHCl}_3$  ( $\text{cm}^{-1}$ ): 3440, 1695, 1655, 1525, 1350, 1120

NMR  $\delta$  ( $\text{CDCl}_3$ ) : 2.35 (3H, s), 5.21 (2H, s), 5.93 (2H, s), 7.52 (2H, d, J=9Hz), 8.22 (2H, d, J=9Hz) ppm

Reference Example 1-8



40 mg of (2S,4S)-1-(p-nitrobenzyloxycarbonyl)-2-dimethylcarbamoyl-4-acetylthiopyrrolidine was dissolved

in 4 ml of methanol, and 0.1 ml of a 1N sodium hydroxide aqueous solution was added thereto, followed by stirring at room temperature for 15 minutes. 0.11 ml of a 1N hydrochloric acid aqueous solution was then added thereto, followed by concentration under reduced pressure. The concentrate was diluted with ethyl acetate, washed with water, dried over sodium sulfate and distilled off to remove the solvent to obtain (2S,4S)-1-(p-nitrobenzyloxycarbonyl)-2-dimethyl-

5 carbamoyl-4-mercaptopyrrolidine.

10

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1705, 1650, 1515, 1400, 1340,  
1165, 1105


NMR  $\delta$  (CDCl<sub>3</sub>): 1.90 (1H, d, J=8Hz), 2.97 (3H, s), 3.08 (3H, s), 5.19 (2H, s),  
15 7.48 (2H, d, J=9Hz), 8.15 (2H, d, J=9Hz) ppm

In the same manner as described in Reference Example 1-5 but using the corresponding amines, the following thioacetate derivatives shown in Table 1 were

20 obtained.




Table 1

Reference  
Example No.


Y

Spectral Data


1-9

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1700, 1660(sh), 1520, 1405, 1345, 1115

1-10

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 3300, 1695, 1655, 1525, 1415, 1348, 1265, 1105

1-11


IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1700, 1652, 1518, 1400, 1342, 1110NMR<sub>δ</sub> (CDCl<sub>3</sub>): 1.13(3H, d, J=6Hz), 1.15(3H, d, J=6Hz), 2.34(3H, s), 5.26(2H, s), 7.53(2H, d, J=9Hz), 8.21(2H, d, J=9Hz)

Reference  
Example No.

Y

Spectral Data

1-12




IR $\nu_{\text{max}}$  (neat  $\text{cm}^{-1}$ ): 3320, 1680, 1520, 1430, 1405, 1345, 1120

NMR $\delta$  ( $\text{CDCl}_3$ ): 2.32(3H, s), 5.17(2H, br, s), 7.43(2H, d,  $J=9\text{Hz}$ )  
8.10(2H, d,  $J=9\text{Hz}$ )

m.p. 163-167°C


1-13



IR $\nu_{\text{max}}$  (neat  $\text{cm}^{-1}$ ): 3400(br), 1685, 1640(sh), 1517, 1403, 1342, 1212  
1115

NMR $\delta$  ( $\text{CDCl}_3$ ): 2.33(3H, s), 2.97(3H, s), 5.20(2H, s), 7.49(2H, d,  $J=9\text{Hz}$ ), 8.19(2H, d,  $J=9\text{Hz}$ )

1-14



IR $\nu_{\text{max}}$  (neat  $\text{cm}^{-1}$ ): 1710, 1660, 1525, 1400, 1345, 1255, 1110

NMR $\delta$  ( $\text{CDCl}_3$ ): 2.28(3H, s), 2.30(6H, s), 2.50(3H, s), 5.17(2H, s), 7.42(2H, d,  $J=8.5\text{Hz}$ ), 8.13(2H, d,  $J=8.5\text{Hz}$ )


0126587

Reference  
Example No.

Y

Spectral Data


1-15



IR $\nu_{\text{max}}$  (neat  $\text{cm}^{-1}$ ): 3320, 1700, 1650, 1520, 1405, 1345, 1220, 1110

NMR $\delta$  ( $\text{CDCl}_3$ ): 2.33(3H, s), 2.93(3H, s), 5.23(2H, s), 7.27(5H, br, s)


1-16



IR $\nu_{\text{max}}$  (neat  $\text{cm}^{-1}$ ): 1710, 1650, 1525, 1425, 1345, 1245, 1025, 962

NMR $\delta$  ( $\text{CDCl}_3$ ): 1.58(6H, m), 2.32(3H, s), 5.22(2H, s)

1-17



IR $\nu_{\text{max}}$  (neat  $\text{cm}^{-1}$ ): 1710, 1655, 1520, 1430, 1400, 1345, 1115


NMR $\delta$  ( $\text{CDCl}_3$ ): 2.31(3H, s), 5.20(2H, s), 7.47(2H, d,  $J=9\text{Hz}$ ), 8.18(2H, d,  $J=9\text{Hz}$ )

Reference  
Example No.

Y


Spectral Data

1-18




IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1700, 1650(sh), 1520, 1435, 1340, 1290, 1235, 1110, 1000

1-19



IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1710, 1650, 1520, 1350, 1110


1-20



IR<sub>max</sub><sup>Nujol</sup> (cm<sup>-1</sup>): 3320, 1700, 1660, 1170, 1110  
m.p. 147-149°C

NMR $\delta$  (CDCl<sub>3</sub>): 2.33(3H, s), 4.68(1H, t, J=8Hz), 5.19(2H, s), 8.18(2H, d, J=8Hz)

1-21



IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1705, 1690, 1520, 1345, 1160, 1110


NMR $\delta$  (CDCl<sub>3</sub>): 2.32(3H, s), 5.22(2H, s), 7.50(2H, d, J=8.5Hz), 8.19(2H, d, J=8.5Hz)

0126587

Reference  
Example No.

Y

## Spectral Data




1-22  
IR<sub>max</sub> Nujol (cm<sup>-1</sup>): 3310, 1710, 1635, 1520, 1170, 1120  
m.p. 200-206°C




1-23  
IR<sub>max</sub> neat (cm<sup>-1</sup>): 3400, 1700, 1665, 1525, 1345, 1120


NMR<sub>δ</sub> (CDCl<sub>3</sub>): 2.33(3H, s), 7.50(2H, d, J=9Hz), 8.20(2H, d, J=9Hz)



1-24  
IR<sub>max</sub> Nujol (cm<sup>-1</sup>): 3400, 3300, 3220, 1700, 1655, 1180, 1110  
m.p. 203-209°C



1-25  
IR<sub>max</sub> Nujol (cm<sup>-1</sup>): 3300, 1740, 1700, 1650, 1520, 1180  
m.p. 185-188°C



1-26  
IR<sub>max</sub> neat (cm<sup>-1</sup>): 3350, 3230, 1695, 1525, 1410, 1350


NMR<sub>δ</sub> (CDCl<sub>3</sub>): 2.37(3H, s), 3.23(3H, s), 5.20(2H, s), 7.50(2H, d, J=9Hz), 8.27(2H, d, J=9Hz)

Reference  
Example No.

Y

Spectral Data

1-27




IR<sub>max</sub>  $\text{CHCl}_3$  ( $\text{cm}^{-1}$ ): 3350, 1690, 1660, 1520, 1340, 1120

NMR $\delta$  ( $\text{CDCl}_3$ ):

2.36(3H, s), 3.21(2H, s), 5.23(2H, s), 6.93(1H  
br.s), 7.50(2H, d, J=9Hz), 8.25(2H, d, J=9Hz)

1-28




IR<sub>max</sub>  $\text{CHCl}_3$  ( $\text{cm}^{-1}$ ): 1700, 1650, 1520, 1340, 1110

NMR $\delta$  ( $\text{CDCl}_3$ ):

2.33(3H, s), 7.43(2H, d, J=8Hz), 8.20(2H, d,  
J=8Hz)

1-29



IR<sub>max</sub>  $\text{neat}$  ( $\text{cm}^{-1}$ ): 1695, 1655, 1525, 1427, 1342, 1250, 1110, 1065,  
955

NMR $\delta$  ( $\text{CDCl}_3$ ):


2.32(3H, s), 5.21(2H, s), 7.48(2H, d, J=8.5Hz),  
8.18(2H, d, J=8.5Hz)

Reference  
Example No.

Y

Spectral Data


1-30



$\text{CHCl}_3$   
 $\text{IR}_{\text{max}}$  ( $\text{cm}^{-1}$ ): 3400, 1700, 1520, 1440, 1345, 1115

$\text{NMR}_\delta$  ( $\text{CDCl}_3$ ): 2.33(3H, s), 8.20(2H, d,  $J=9\text{Hz}$ )  
m.p. 150-151°C


1-31



$\text{CHCl}_3$   
 $\text{IR}_{\text{max}}$  ( $\text{cm}^{-1}$ ): 3300, 1700, 1525, 1345, 1120

$\text{NMR}_\delta$  ( $\text{CDCl}_3$ ): 2.33(3H, s), 5.25(2H, s), 7.47(2H, d,  $J=9\text{Hz}$ ),  
8.58(1H, d,  $J=3\text{Hz}$ ), 9.50(1H, br.s)


1-32



$\text{IR}_{\text{max}}^{\text{neat}}$  ( $\text{cm}^{-1}$ ): 1705, 1655, 1520, 1430, 1400, 1342, 1112

$\text{NMR}_\delta$  ( $\text{CDCl}_3$ ): 2.33(3H, s), 5.20(2H, s), 7.47(2H, d,  $J=8.5\text{Hz}$ )  
8.17(2H, d,  $J=8.5\text{Hz}$ )

1-33



$\text{CHCl}_3$   
 $\text{IR}_{\text{max}}$  ( $\text{cm}^{-1}$ ): 1705, 1660, 1525, 1345, 1120

$\text{NMR}_\delta$  ( $\text{CDCl}_3$ ): 2.35(3H, s), 5.23(2H, s), 7.55(2H, d,  $J=9\text{Hz}$ )

Reference  
Example No.

Y

Spectral Data

1-34




IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1705, 1640, 1516, 1430, 1400, 1342, 1110

NMR<sub>δ</sub> (CDCl<sub>3</sub>):


2.31(3H, s), 4.03(2H, dd, J=6 and 8Hz), 4.53(1H, t, J=8Hz), 5.19(2H, s), 7.48(2H, d, J=9Hz), 8.18(2H, d, J=9Hz)

1-35



IR<sub>max</sub><sup>Nujol</sup> (cm<sup>-1</sup>): 3430, 1700, 1640, 1345, 1245, 1120  
m.p. 173-175°C

1-36




IR<sub>max</sub><sup>CHCl<sub>3</sub></sup> (cm<sup>-1</sup>): 3400, 1700, 1650, 1525, 1345, 1120

NMR<sub>δ</sub> (CDCl<sub>3</sub>):

2.33(3H, s), 5.17(2H, s), 7.47(2H, d, J=9Hz), 8.18(2H, d, J=9Hz)

1-37



IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1700, 1640, 1520, 1400, 1335, 1100

NMR<sub>δ</sub> (CDCl<sub>3</sub>):


2.33(3H, s), 5.22(2H, s), 7.50(2H, d, J=9Hz), 8.20(2H, d, J=9Hz)



Reference  
Example No.

Y


Spectral Data



1-38

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1710, 1640, 1525, 1345, 1120


NMR<sub>δ</sub> (CDCl<sub>3</sub>): 2.35(3H, s), 5.25(2H, s), 7.53(2H, d, J=9H), 8.23(2H, d, J=9Hz)



1-39

IR<sub>max</sub><sup>CHCl<sub>3</sub></sup> (cm<sup>-1</sup>): 1700, 1610, 1520, 1400, 1350, 1110

NMR<sub>δ</sub> (CDCl<sub>3</sub>): 2.33(3H, s), 2.87(6H, s), 2.95(6H, s), 5.25(2H, s), 7.56(2H, d, J=9Hz), 8.22(2H, d, J=9Hz)



1-40

IR<sub>max</sub><sup>CHCl<sub>3</sub></sup> (cm<sup>-1</sup>): 3350, 1705, 1610, 1525, 1345, 1120

NMR<sub>δ</sub> (CDCl<sub>3</sub>): 2.33(3H, s), 5.23(2H, s), 8.15(2H, d, J=8Hz)



1-41

IR<sub>max</sub><sup>Nujol</sup> (cm<sup>-1</sup>): 1750, 1705, 1690, 1523, 1441, 1352, 1226, 1170, 1114

m.p. 92-93.5°C

0126587

Reference  
Example No.

Y

Spectral Data

1-42	$-\text{OC}_2\text{H}_5$	IR <sub>ν</sub> <sup>Nujol</sup> <sub>max</sub> (cm <sup>-1</sup> ): 1748, 1712, 1692, 1524, 1440, 1348, 1223, 1200 m.p. 80-81.5°C
1-43	$-\text{NHNH}_2$	IR <sub>ν</sub> <sup>Nujol</sup> <sub>max</sub> (cm <sup>-1</sup> ): 3200, 1720, 1615, 1520, 1350, 1125 m.p. 208-213°C
1-44	$-\text{NHN}(\text{CH}_3)_2$	IR <sub>ν</sub> <sup>Nujol</sup> <sub>max</sub> (cm <sup>-1</sup> ): 3200, 1710, 1660, 1520, 1340, 1175 m.p. 158-159°C
1-45	$\begin{array}{c} \text{CH}_3 \\ \diagdown \\ -\text{N} \\ \diagup \\ \text{N}(\text{CH}_3)_2 \end{array}$	IR <sub>ν</sub> <sup>neat</sup> <sub>max</sub> (cm <sup>-1</sup> ): 1715, 1670, 1520, 1340, 1110  NMRδ (CDCl <sub>3</sub> ): 2.32(3H, s), 5.18(2H, s)
1-46	$-\text{NHOPNB}$	IR <sub>ν</sub> <sup>Nujol</sup> <sub>max</sub> (cm <sup>-1</sup> ): 3200, 1730, 1700, 1680, 1520, 1340, 1120 m.p. 166-167°C
1-47	$-\text{NHOCCH}_3$	IR <sub>ν</sub> <sup>Nujol</sup> <sub>max</sub> (cm <sup>-1</sup> ): 3240, 1705, 1690, 1520, 1340, 1175 m.p. 178-179°C


0126587

Reference  
Example No.

Y

Spectral Data

1-48



IR<sub>ν</sub><sup>neat</sup> (cm<sup>-1</sup>): 1695, 1595, 1520, 1340, 1180, 1110  
max

NMR<sub>δ</sub> (CDCl<sub>3</sub>): 2.34(3H, s), 5.31(2H, s), 7.42(2H, d, J=5Hz),  
8.48(2H, d, J=6Hz)


1-49



IR<sub>ν</sub><sup>neat</sup> (cm<sup>-1</sup>): 1695, 1600, 1520, 1340, 1110  
max

NMR<sub>δ</sub> (CDCl<sub>3</sub>): 2.34(4H, s), 2.39(3H, s), 5.18(2H, s), 7.48(2H,  
d, J=8.5Hz), 8.21(2H, d, J=8.5Hz)

0126587


Reference Example 2-1

3.10 g of trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-proline and 1.10 g of triethylamine were dissolved in 40 ml of dried tetrahydrofuran, and a solution of 1.20 g of ethyl chloroformate in 10 ml of dried tetrahydrofuran was added dropwise thereto at -25°C to -35°C. After stirring at the same temperature for 50 minutes, 10 ml of concentrated aqueous ammonia was added dropwise to the mixture at -25° to -40°C. The temperature was then gradually elevated to room temperature, and the reaction mixture was stirred for 1 hour, followed by concentration under reduced pressure. To the residue were added 20 ml of water and 50 ml of diethyl ether. After ice-cooling, the thus formed white crystals were separated by filtration, washed successively with cool water and cool diethyl ether, and dried under reduced pressure to yield trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-prolineamide.

Melting Point : 163.3-164.0°C

IR<sub>max</sub><sup>Nujol</sup> (cm<sup>-1</sup>): 3460, 3370, 3200, 1687, 1640, 1621,

1539, 1341, 1180, 1078


Reference Example 2-2

A solution of 1.89 g of methanesulfonyl chloride in 10 ml of dried tetrahydrofuran was added dropwise to a suspension of 2.32 g of trans-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-prolineamide and 1.67 g of triethylamine in 40 ml of dried tetrahydrofuran at room temperature. After stirring for 1 hour, the reaction mixture was concentrated under reduced pressure, and to the residue were added 30 ml of water and 30 ml of diethyl ether. After cooling, the resulting white crystals were separated by filtration, washed successively with cool water and cool diethyl ether and dried under reduced pressure to obtain trans-1-(p-nitrobenzyloxycarbonyl)-4-methanesulfonyloxy-L-prolineamide.

Melting Point : 149.5-151°C

IR<sub>max</sub><sup>Nujol</sup> (cm<sup>-1</sup>): 3400, 3225, 1715, 1675, 1520, 1340, 1170, 1135

Reference Example 2-3



A solution of 642 mg of thioacetic acid in 14 ml of dried dimethylformamide was added to a suspension of 374 mg of 50% sodium hydride in 13 ml of dried dimethylformamide in a nitrogen stream, followed by stirring at room temperature for 25 minutes. To the mixture were added 975 mg of sodium iodide and then a solution of 2.52 g of trans-1-(p-nitrobenzyloxy-carbonyl)-4-methanesulfonyloxy-L-prolineamide in 12 ml of dried dimethylformamide, and the resulting mixture was heated at 70°C for 6 hours while stirring. The reaction mixture was poured into a cool aqueous solution of sodium chloride and extracted with benzene. The extract was washed successively with a 10% aqueous solution of sodium sulfite and a sodium chloride aqueous solution, dried over sodium sulfate and distilled off to remove the solvent. The resulting crude crystals were washed with a warm mixed solvent of tetrahydrofuran and benzene to obtain cis-1-(p-nitrobenzyloxycarbonyl)-4-acetylthio-L-prolineamide.


Melting Point : 168.5-169.5°C

IR<sup>Nujol</sup><sub>max</sub> (cm<sup>-1</sup>): 3350, 3180, 1715, 1690, 1638,  
1510, 1330, 1100

[α]<sub>D</sub><sup>30</sup> -23° (c=0.334, DMF)

Reference Example 2-4

5



10


15

950 mg of (2S,4S)-1-(p-nitrobenzyloxycarbonyl)-2-carbamoyl-4-acetylthiopyrrolidine was dissolved in 95 ml of methanol, and 2.59 ml of a 1N aqueous solution of sodium hydroxide was added thereto at room temperature in an argon stream, followed by stirring at that temperature for 15 minutes. The reaction mixture was neutralized with 2.59 ml of a 1N aqueous solution of hydrochloric acid and distilled off under reduced pressure to remove the methanol. The thus precipitated crystals were filtered and washed with water to obtain (2S,4S)-1-(p-nitrobenzyloxycarbonyl)-2-carbamoyl-4-mercaptopyrrolidine.

Melting Point: 158-162°C


Cis-compound: IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 3400 (br.), 1725, 1515, 1405, 1350, 1250, 1170, 1120  
 NMR  $\delta$  (CDCl<sub>3</sub>): 3.78 (3H, s), 5.08 (2H, s), 6.82 (2H, d, J=9Hz), 8.12 (2H, d, J=9Hz) ppm

Reference Example 3-3



In the same manner as described in Reference Examples 1-3 and 1-4 but using 610 mg of cis-1-(p-nitrobenzyloxycarbonyl)-4-hydroxy-L-proline p-methoxybenzyl ester, trans-1-(p-nitrobenzyloxycarbonyl)-4-acetylthio-L-proline was obtained.

Reference Example 3-4



a) In the same manner as described in Reference Example 1-5 but using 180 mg of trans-1-(p-nitrobenzyloxycarbonyl)-4-acetylthio-L-proline, 100 mg of (2S,4R)-1-



(p-nitrobenzyloxycarbonyl)-2-dimethylcarbamoyl-4-acetylthiopyrrolidine was obtained.

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1700, 1655, 1515, 1400, 1340, 1115

[α]<sub>D</sub><sup>30</sup> +32.8° (c=0.375, acetone)

- 5      b)      In the same manner as described in Reference Example 1-8 but using 80 mg of the thioacetate derivative prepared as in a) above, (2S,4R)-1-(p-nitrobenzyloxycarbonyl)-2-dimethylcarbamoyl-4-mercaptopyrrolidine was obtained.


IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1700, 1650, 1510, 1420, 1400, 1340, 1120

10


NMR δ (CDCl<sub>3</sub>): 1.77 (1H, d, J=7Hz), 2.97 (3H, s), 3.16 (3H, s), 5.22 (2H, s), 8.16 (2H, d, J=8.5Hz) ppm

- 15      In the same manner as described in Reference Example 3-4 but using the corresponding amines, the following thioacetates and mercaptans as shown in Table 2 were obtained.

Table 2



Reference Example No.	B	Y	Spectral Data
3-5	Ac	-NH <sub>2</sub>	IR <sub>max</sub> <sup>neat</sup> (cm <sup>-1</sup> ): 3300(br), 1700(sh), 1685, 1512, 1430, 1400, 1345, 1175, 1115
			[α] <sub>D</sub> <sup>30</sup> + 7.36° (c=0.625, acetone)
			IR <sub>max</sub> <sup>neat</sup> (cm <sup>-1</sup> ): 1700, 1685, 1515, 1435, 1400, 1342, 1118
	H	-NH <sub>2</sub>	NMRδ (CDCl <sub>3</sub> ): 2.26(1H, d, J=7Hz), 5.22(2H, s), 8.11(2H, d, J=8.5Hz)
3-6	Ac		IR <sub>max</sub> <sup>KBr</sup> (cm <sup>-1</sup> ): 1705, 1645, 1517, 1435, 1400, 1340, 1115
			NMRδ (CDCl <sub>3</sub> ): 2.33(3H, s), 5.22(2H, s), 8.16(2H, d, J=9Hz)
	H		IR <sub>max</sub> <sup>neat</sup> (cm <sup>-1</sup> ): 1705, 1640, 1515, 1430, 1110


Reference Example 4-1.

166 mg of cis-1-p-nitrobenzyloxycarbonyl-4-hydroxy-D-proline p-methoxybenzyl ester, which was  
 5 obtained from cis-4-hydroxy-D-proline in the same manner as in Reference Examples 1-1 and 1-2, and 202 mg of triphenylphosphine were dissolved in 1.5 ml of dried tetrahydrofuran, and 27 mg of formic acid was added to the solution. 134 mg of diethyl azodicarboxylate  
 10 further added thereto at room temperature in a nitrogen stream. After stirring for 30 minutes, the solvent was removed by distillation. The residue was purified by silica gel chromatography to obtain trans-1-p-nitrobenzyloxycarbonyl-4-formyloxy-D-proline p-methoxybenzyl  
 15 ester.

IR<sup>neat</sup><sub>max</sub> (cm<sup>-1</sup>): 1720, 1515, 1402, 1342, 1245,  
 1165, 1120

0126587

Table 3



Reference  
Example No.

B

Y

Spectral Data

IR<sub>neat</sub> (cm<sup>-1</sup>): 1705(sh), 1685, 1520, 1425, 1402, 1342, 1122  
 max  
 $[\alpha]_D^{30}$  - 6.92° (c=0.665, acetone)

5-2

Ac

-NH<sub>2</sub>

IR<sub>max</sub><sup>CHCl<sub>3</sub></sup> (cm<sup>-1</sup>): 1695(sh), 1682, 1515, 1395, 1340, 1115

H

-NH<sub>2</sub>

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1695, 1635, 1515, 1430, 1395, 1340, 1115


Ac



5-3

IR<sub>max</sub><sup>CHCl<sub>3</sub></sup> (cm<sup>-1</sup>): 1700, 1640, 1520, 1422, 1345, 1120

H



Reference Example No.	B	Y	Spectral Data
--------------------------	---	---	---------------

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1700, 1655, 1620, 1605, 1520, 1340, 1115



Ac

NMR<sub>δ</sub> (CDCl<sub>3</sub>): 2.33(3H, s), 5.22(2H, s), 7.49(2H, d, J=8.5Hz), 8.21(2H, d, J=8.5Hz)

5-4.


[α]<sub>D</sub><sup>23</sup> -21° (c=0.25, acetone)



H

IR<sub>max</sub><sup>CHCl<sub>3</sub></sup> (cm<sup>-1</sup>): 1705, 1660, 1525, 1340, 1120


0126587

Reference Example 6-1

In the same manner as described in Reference Example 1-2 but using 500 mg of trans-1-p-nitrobenzyloxycarbonyl-4-hydroxy-L-proline and 383 mg of p-nitrobenzyl bromide, trans-1-p-nitrobenzyloxycarbonyl-4-hydroxy-L-proline p-nitrobenzyl ester was obtained.

IR<sub>max</sub><sup>CHCl<sub>3</sub></sup> (cm<sup>-1</sup>): 3380 (br.), 1750, 1705, 1520, 1425, 1400, 1342, 1160

NMR δ (CDCl<sub>3</sub>) : 2.20 (3H, m), 3.67 (2H, d, J=3Hz), 4.60 (2H, t, J=8Hz), 5.15 (2H, s), 5.23 (2H, ABq.), 7.47 (4H, d, J=8.5Hz), 8.15 (4H, d, J=8.5Hz) ppm

Reference Example 6-2


In the same manner as described in Reference Examples 1-3 and 1-8 but using trans-1-p-nitrobenzyloxycarbonyl

4-hydroxy-L-proline p-nitrobenzyl ester, cis-1-p-nitrobenzyloxycarbonyl-4-mercapto-L-proline p-nitrobenzyl ester was obtained.

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1700, 1685, 1600, 1510, 1430,  
1400, 1340, 1105

5

Reference Example 6-3



- a) 115 mg of cis-1-p-nitrobenzyloxycarbonyl-4-mercapto-L-proline p-nitrobenzyl ester was dissolved in 3 ml of dried tetrahydrofuran, and 30 mg of triethylamine was added thereto. Then, 28.5 mg of ethyl chloroformate was added dropwise thereto under ice-cooling, followed by stirring for 10 minutes. The reaction mixture was diluted with ethyl acetate, washed successively with dilute hydrochloric acid and water, and dried over sodium sulfate. The solvent was removed by distillation to give 133 mg of cis-1-p-nitrobenzyloxycarbonyl-4-ethoxycarbonylthio-L-proline p-nitrobenzyl ester.


$\text{IR}_{\text{max}}^{\text{neat}}$  ( $\text{cm}^{-1}$ ): 1755, 1710, 1610, 1525, 1405, 1350,  
1160, 1015, 850

b) 133 mg of the thus obtained ester derivative was dissolved in 5 ml of a mixture of tetrahydrofuran and water (1:1 by volume), and 0.26 ml of a 1N aqueous solution of sodium hydroxide was added thereto. After stirring at room temperature for 2.5 hours, 0.3 ml of a 1N hydrochloric acid aqueous solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with water, dried over sodium sulfate and distilled off to remove the solvent. The residue was subjected to silica gel thin layer chromatography to obtain cis-1-p-nitrobenzyloxy-carbonyl-4-ethoxycarbonylthio-L-proline.


$\text{IR}_{\text{max}}^{\text{neat}}$  ( $\text{cm}^{-1}$ ): 1700, 1520, 1400, 1340, 1165, 1145

NMR  $\delta$  ( $\text{CDCl}_3$ ): 1.30 (3H, t,  $J=7\text{Hz}$ ), 4.28 (2H, q,  $J=7\text{Hz}$ ), 5.24 (2H, s), 7.50 (2H, d,  $J=9\text{Hz}$ ), 8.17 (2H, d,  $J=9\text{Hz}$ ) ppm

Reference Example 6-4







a) 72 mg of cis-1-p-nitrobenzyloxycarbonyl-4-ethoxycarbonylthio-L-proline was dissolved in 3 ml of dried tetrahydrofuran, and 40 mg of triethylamine was added thereto. Under ice-cooling, 41 mg of ethyl chloroformate was added dropwise thereto, followed by stirring for 15 minutes. 1.5 ml of a 40% aqueous solution of methylamine was added dropwise to the mixture, followed by stirring for 15 minutes. The reaction mixture was diluted with ethyl acetate, washed successively with dilute hydrochloric acid and water, dried over sodium sulfate and distilled off to remove the solvent, thereby to obtain (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-methylcarbamoyl-4-ethoxycarbonylthio-pyrrolidine.

IR<sub>max</sub><sup>Nujol</sup> (cm<sup>-1</sup>): 3290, 1705, 1660, 1520, 1425, 1405, 1345, 1180, 1160

NMR  $\delta$  (CDCl<sub>3</sub>): 1.30 (3H, t, J=8Hz), 2.80 (3H, d, J=5Hz), 4.27 (2H, q, J=8Hz), 5.22 (2H, s), 7.48 (2H, d, J=9Hz), 8.18 (2H, d, J=9Hz) ppm

b) 82 mg of the methylcarbamoyl derivative as


prepared in a) above was dissolved in 4 ml of a mixture of methanol and water (1:1 by volume), and 0.25 ml of a 1N aqueous solution of sodium hydroxide was added thereto. After stirring at room temperature for 30 minutes, 0.27 ml of a 1N hydrochloric acid aqueous solution was added thereto. The resulting mixture was extracted with ethyl acetate, and the extract was washed with water, dried over sodium sulfate and distilled off to remove the solvent, thereby to obtain (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-methylcarbamoyl-4-mercaptopyrrolidine.

IR<sub>max</sub><sup>Nujol</sup> (cm<sup>-1</sup>): 3280, 1710, 1650, 1510, 1340, 1165

NMR  $\delta$  (CDCl<sub>3</sub>) : 2.79 (3H, d, J=5Hz), 4.27 (2H, t, J=8Hz), 5.23 (2H, s), 7.50 (2H, d, J=9Hz), 8.20 (2H, d, J=9Hz) ppm

In the same manner as described in Reference Example 6-4(a) but using the corresponding amines, the following thiocarbonates as shown in Table 4 were obtained.

Table 4




Reference  
Example No.

Y

Spectral Data

6-5




IR,  $\nu_{\text{max}}$  (neat,  $\text{cm}^{-1}$ ): 3350, 1705, 1520, 1405, 1345, 1170, 1150

NMR  $\delta$  ( $\text{CDCl}_3$ ):

1.27(3H, t,  $J=7\text{Hz}$ ), 4.23(2H, q,  $J=7\text{Hz}$ ), 5.18(2H, s), 7.44(2H, d,  $J=9\text{Hz}$ ), 8.13(2H, d,  $J=9\text{Hz}$ )

6-6



IR,  $\nu_{\text{max}}$  (neat,  $\text{cm}^{-1}$ ): 1710, 1520, 1400, 1345, 1170, 1148


NMR  $\delta$  ( $\text{CDCl}_3$ ):

1.28(3H, t,  $J=7\text{Hz}$ ), 2.19(6H, s), 4.24(2H, q,  $J=7\text{Hz}$ ), 5.20(2H, s), 7.47(2H, d,  $J=9\text{Hz}$ ), 8.13(2H, d,  $J=9\text{Hz}$ )

0126587

The following mercaptans as shown in Table 5 were obtained in the same manner as described in Reference Example 1-8 or 6-4(b).

Table 5




Reference  
Example No.

Y


Spectral Data

7-1




IR<sub>max</sub><sup>neat</sup> ( $\text{cm}^{-1}$ ): 1705, 1640, 1520, 1430, 1400, 1345, 1105

7-2




IR<sub>max</sub><sup>neat</sup> ( $\text{cm}^{-1}$ ): 3290, 1710, 1650, 1520, 1403, 1340

7-3



IR<sub>max</sub><sup>neat</sup> ( $\text{cm}^{-1}$ ): 3290, 1717, 1660, 1520, 1410, 1350

7-4




IR<sub>max</sub><sup>Nujol</sup> ( $\text{cm}^{-1}$ ): 3420, 3300, 1700(sh), 1675, 1640, 1510, 1340

Reference  
Example No.

Y

Spectral Data


7-5



IR<sub>max</sub> Nujol (cm<sup>-1</sup>): 3270, 1710, 1650, 1505, 1340


NMR δ (CDCl<sub>3</sub>): 5.20(2H, s), 7.49(2H, q, J=8.5Hz), 8.16(2H, d, J=8.5Hz)

7-6




IR<sub>max</sub> neat (cm<sup>-1</sup>): 3400, 1690, 1640, 1515, 1405, 1345

7-7




IR<sub>max</sub> neat (cm<sup>-1</sup>): 1705, 1650, 1515, 1400, 1340

7-8




IR<sub>max</sub> neat (cm<sup>-1</sup>): 1710, 1645, 1520, 1440, 1345, 1245, 1025

7-9



IR<sub>max</sub> neat (cm<sup>-1</sup>): 1710, 1655, 1520, 1430, 1405, 1342, 1112

7-10




IR<sub>max</sub> neat (cm<sup>-1</sup>): 1710, 1650, 1520, 1405, 1345, 1205

Reference  
Example No.

Y

Spectral Data

7-11




IR<sub>Nujol</sub> (cm<sup>-1</sup>): 3300, 1725, 1660, 1520, 1345, 1110  
max

7-12



IR<sub>neat</sub> (cm<sup>-1</sup>): 3280, 1730(sh), 1710, 1645, 1510, 1340  
max

7-13




IR<sub>Nujol</sub> (cm<sup>-1</sup>): 3320, 1725, 1640, 1520, 1405, 1345  
max

7-14




NMR δ (CDCl<sub>3</sub>): 1.87(1H, d, J=7Hz), 2.96(3H, s), 2.98(3H, s),  
4.33(1H, t, J=7.5Hz), 5.24(2H, s), 7.48(2H, d, J=9Hz), 8.18(2H, d, J=9Hz)

7-15



IR<sub>Nujol</sub> (cm<sup>-1</sup>): 3300, 1700, 1680, 1655, 1520, 1345  
max

7-16




IR<sub>Nujol</sub> (cm<sup>-1</sup>): 3310, 1722, 1650, 1525, 1350  
max

Reference  
Example No.

Y'


Spectral Data

7-17




IR, Nujol ( $\text{cm}^{-1}$ ): 3325, 1710, 1640, 1520, 1345  
max

7-18




IR, neat ( $\text{cm}^{-1}$ ): 3350(br), 1690, 1660(sh), 1520, 1405, 1345  
max

7-19




IR, neat ( $\text{cm}^{-1}$ ): 3370, 1700, 1665, 1525, 1410, 1350  
max

7-20




IR, neat ( $\text{cm}^{-1}$ ): 3500, 1710, 1660, 1520, 1405, 1345  
max

7-21



IR, neat ( $\text{cm}^{-1}$ ): 3245, 1700, 1645, 1520, 1340, 1190, 1165, 1107,  
max 1065, 950, 850

7-22



IR,  $\text{CHCl}_3$  ( $\text{cm}^{-1}$ ): 3410, 1710, 1525, 1440, 1345, 1305  
max

0126587




Reference  
Example No.

Y

Spectral Data

7-23



IR, Nujol (cm<sup>-1</sup>): 3250, 1710, 1670, 1525, 1345, 1175

7-24




IR, neat (cm<sup>-1</sup>): 1710, 1650, 1518, 1435, 1400, 1345, 1170, 1110

7-25




IR, CHCl<sub>3</sub> max (cm<sup>-1</sup>): 1710, 1660, 1520, 1345, 1170, 1110

7-26



IR, CHCl<sub>3</sub> max (cm<sup>-1</sup>): 1720, 1525, 1470, 1340, 1170, 1110

7-27



IR, CHCl<sub>3</sub> max (cm<sup>-1</sup>): 3470(br), 1700, 1640, 1520, 1340, 1120

7-28



IR, CHCl<sub>3</sub> max (cm<sup>-1</sup>): 3420(br), 1700, 1645, 1520, 1340, 1165

7-29




IR, CHCl<sub>3</sub> max (cm<sup>-1</sup>): 1710, 1640, 1525, 1345, 1170, 1015

Reference  
Example No.


Y

Spectral Data




7-30

NMR  $\delta$  (CDCl<sub>3</sub>): 1.95(1H, d, J=8Hz), 5.25(2H, s), 7.52(2H, s),  
J=9Hz), 8.21(2H, d, J=9Hz)



7-31

IR<sub>max</sub> (neat) (cm<sup>-1</sup>): 1705, 1600, 1520, 1400, 1340, 1160




7-32

IR<sub>max</sub> (CHCl<sub>3</sub>) (cm<sup>-1</sup>): 3420, 1695, 1610, 1522, 1350-1110



7-33

IR<sub>max</sub> (neat) (cm<sup>-1</sup>): 1745, 1710, 1605, 1520, 1430, 1400, 1345, 1205,  
1167, 1110



7-34

IR<sub>max</sub> (neat) (cm<sup>-1</sup>): 1740, 1710, 1522, 1430, 1402, 1342, 1200, 1170,  
1110



7-35

IR<sub>max</sub> (Nujol) (cm<sup>-1</sup>): 3180, 3050, 1720, 1615, 1520, 1350


0126587

Reference  
Example No.

Y

## Spectral Data


7-36

IR<sub>max</sub><sup>Nujol</sup> (cm<sup>-1</sup>): 3205, 1720, 1660, 1520, 1345, 1180

7-37

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1706, 1662, 1520, 1340, 1165, 1105


7-38

IR<sub>max</sub><sup>Nujol</sup> (cm<sup>-1</sup>): 3200, 1715, 1665, 1515, 1345, 1170

7-39

IR<sub>max</sub><sup>Nujol</sup> (cm<sup>-1</sup>): 3200, 1715, 1670, 1520, 1340, 1170

7-40

IR<sub>max</sub><sup>CHCl<sub>3</sub></sup> (cm<sup>-1</sup>): 1690, 1650, 1525, 1405, 1345, 1170, 1110

7-41


IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1700, 1520, 1400, 1340, 1200, 1160, 1105

7-42

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1708, 1645, 1520, 1440, 1405, 1350, 1170, 1115

7-43

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1700, 1600, 1515, 1105

Reference Example 8-1

a) In the same manner as described in Reference Example 1-1 but using 10 g of trans-4-hydroxy-L-proline and 23.2 g of S-p-methoxybenzyloxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine, trans-1-(p-methoxybenzyloxycarbonyl)-4-hydroxy-L-proline was obtained.

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 3400 (br.), 1692, 1430, 1355, 1245, 1170, 1122

10 NMR  $\delta$  (CDCl<sub>3</sub>): 2.23 (2H, m), 3.73 (3H, s), 5.00 (2H, s), 6.78 (2H, d, J=9Hz), 7.20 (2H, d, J=9Hz) ppm

b) In the same manner as described in Reference Example 2-1 but using 0.57 g of the proline derivative as prepared in a) above and 0.215 g of benzylamine, trans-1-p-methoxybenzyloxycarbonyl-4-hydroxy-L-benzyl-prolineamide was obtained.

IR<sub>max</sub><sup>Nujol</sup> (cm<sup>-1</sup>): 3375, 3300, 1665, 1248, 1165,  
1120, 1025

NMR  $\delta$  (CDCl<sub>3</sub>) : 3.76 (3H, s), 4.35 (4H, m),  
4.96 (2H, s), 6.79 (2H, d, J=  
9Hz), 7.20 (5H, s) ppm

5

c) In the same manner as described in Reference  
Example 1-3 but using 0.5 g of the benzylprolineamide  
as prepared in b) above, (2S,4S)-1-p-methoxybenzyloxy-  
carbonyl-2-benzylcarbamoyl-4-acetylthiopyrrolidine was  
obtained.


10

IR<sub>max</sub><sup>Nujol</sup> (cm<sup>-1</sup>): 3280, 1690, 1675, 1240

NMR  $\delta$  (CDCl<sub>3</sub>) : 2.27 (3H, s), 3.82 (3H, s), 4.42  
(2H, d, J=6Hz), 5.05 (2H, s),  
6.87 (2H, d, J=8Hz), 7.23 (2H, d,  
J=8Hz), 7.28 (5H, s) ppm

15

Reference Example 8-2




177 mg of (2S,4S)-1-p-methoxybenzyloxy-carbonyl-2-benzylcarbamoyl-4-acetylthiopyrrolidine and 86 mg of anisole were dissolved in 0.5 ml of trifluoroacetic acid, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate, washed successively with an aqueous solution of sodium bicarbonate and water and dried over sodium sulfate. The solvent was removed by distillation, and the residue was subjected to silica gel thin layer chromatography to obtain (2S,4S)-2-benzylcarbamoyl-4-acetylthiopyrrolidine.

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 3325, 1690, 1510, 1400, 1350, 1120, 950

NMR  $\delta$  (CDCl<sub>3</sub>): 2.28 (3H, s), 3.83 (2H, m), 4.42 (2H, d, J=6Hz), 7.32 (5H, s) ppm

Reference Example 9-1




7 g of 1-(di-p-anisylmethyl)-3-ethenyl-4-carboxy-2-azetidinone was dissolved in 50 ml of dried methylene chloride, and 0.8 ml of dimethylformamide

was added to the resulting solution. 2 ml of oxalyl chloride was added dropwise thereto under ice-cooling, followed by stirring at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and to the concentrate was added 50 ml of dried methylene chloride, followed by concentration again under reduced pressure. The resulting residue was dried in vacuo and then dissolved in 100 ml of dried diethyl ether. The resulting solution was added dropwise under ice-cooling to 120 ml of a 0.17M solution of diazomethane in diethyl ether to which 4 ml of triethylamine had been added, followed by stirring at the same temperature for 1.5 hours. The reaction mixture was diluted with ethyl acetate, washed successively with a 1N aqueous solution of hydrochloric acid and water, dried over sodium sulfate and distilled off to remove the solvent. The resulting oily residue was purified by silica gel chromatography to obtain 1-(di-p-anisylmethyl)-3-ethenyl-4-diazoacetyl-2-azetidinone.

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 2110, 1755, 1640, 1612, 1505, 1240, 1177, 1030, 828  
NMR  $\delta$  (CDCl<sub>3</sub>): 3.78 (6H, s), 5.00 (1H, s), 5.80 (1H, s), 6.84 (4H, d, J=8.5Hz) ppm

Reference Example 9-2



0.7 g of 1-(di-p-anisylmethyl)-3-ethenyl-4-diazoacetyl-2-azetidinone was dissolved in 300 ml of methylene chloride, and 1 ml of water was added thereto.

5 The mixture was irradiated with light for 1 hour using a high pressure mercury lamp while removing oxygen from the system under ice-cooling. Then, the mixture was extracted with a 1N aqueous solution of sodium hydroxide. The aqueous layer was rendered acidic with  
10 hydrochloric acid and extracted with ethyl acetate. The extract was washed with water, dried over sodium sulfate and distilled off to remove the solvent thereby obtaining 1-(di-p-anisylmethyl)-3-ethenyl-4-carboxymethyl-2-azetidinone.


15  $\text{IR}_{\text{max}}^{\text{neat}}$  ( $\text{cm}^{-1}$ ): ~3000, 1700, 1612, 1510, 1300, 1180, 1030, 820

NMR  $\delta$  ( $\text{CDCl}_3$ ): 2.35 (2H, d,  $J=6\text{Hz}$ ), 3.73 (6H, s), 5.80 (1H, s), 6.78 (4H, d,  $J=9.0\text{Hz}$ ), 7.08 (4H, d,  $J=9.0\text{Hz}$ ) ppm

20

Reference Example 9-3






2.3 g of 1-(di-p-anisylmethyl)-3-ethenyl-4-carboxymethyl-2-azetidinone was dissolved in 50 ml of dried dimethylformamide, and 1.5 ml of triethylamine was added thereto. 1.3 g of p-methoxybenzyl chloride was then added dropwise to the mixture, followed by stirring at 70°C for 3 hours. The reaction mixture was diluted with ethyl acetate and diethyl ether, washed successively with dilute hydrochloric acid and water, dried over sodium sulfate and distilled off to remove the solvent thereby obtaining 1-(di-p-anisylmethyl)-3-ethenyl-4-p-methoxybenzyloxycarbonylmethyl-2-azetidinone.

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1750, 1612, 1510, 1250, 1175, 1033

NMR δ (CDCl<sub>3</sub>): 2.36 (2H, d, J=6.5Hz), 3.72 (6H, s), 3.75 (3H, s), 4.83 (2H, s), 5.78 (1H, s) ppm


#### Reference Example 9-4



20 IR<sup>neat</sup><sub>max</sub> (cm<sup>-1</sup>): 3430, 1730, 1615, 1510, 1247,  
1178, 1030, 820  
NMR  $\delta$  (CDCl<sub>3</sub>): 1.23 (3H, d, J=6.5Hz), 2.42 (2H,  
d, J=7Hz), 3.77 (9H, s), 4.95  
(2H, s), 5.78 (1H, s) ppm

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 3430, 1730, 1615, 1510, 1247,  
1178, 1030, 820

NMR  $\delta$  (CDCl<sub>3</sub>): 1.23 (3H, d, J=6.5Hz), 2.42 (2H, d, J=7Hz), 3.77 (9H, s), 4.95 (2H, s), 5.78 (1H, s) ppm

Reference Example 9-5

2.6 g of 1-(di-p-anisylmethyl)-3-(1-hydroxy-ethyl)-4-p-methoxybenzyloxycarbonylmethyl-2-azetidinone  
 5 was dissolved in 15 ml of dried methylene chloride, and 1.22 g of 4-dimethylaminopyridine was added thereto. Under ice-cooling, a solution of 1.3 g of p-nitrobenzyl chloroformate in 7 ml of dried methylene chloride was added dropwise to the mixture, followed by stirring at  
 10 room temperature for 1 hour. To the reaction mixture were added methylene chloride and water, and the methylene chloride layer was washed successively with a 1N hydrochloric acid aqueous solution, water, a 5% aqueous solution of sodium bicarbonate and water, and dried over  
 15 sodium sulfate. The solvent was removed by distillation, and the residue was purified by silica gel chromatography to obtain 2.2 g of 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-p-methoxybenzyloxycarbonylmethyl-2-azetidinone.

20 IR<sup>neat</sup><sub>max</sub> (cm<sup>-1</sup>): 1755, 1610, 1510, 1350, 1245,  
 1175, 1030

NMR  $\delta$  ( $\text{CDCl}_3$ ): 1.35 (3H, d,  $J=6.5\text{Hz}$ ), 2.40  
 (2H, d,  $J=6.5\text{Hz}$ ), 3.09 (1H, dd,  
 $J=2.5$  and  $6\text{Hz}$ ), 3.73 (6H, s),  
 3.77 (3H, s), 4.91 (2H, s), 5.18  
 (2H, s), 5.71 (1H, s) ppm

Reference Example 9-6



2.2 g of 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-p-methoxybenzyloxycarbonylmethyl-2-azetidinone was dissolved in 20 ml of dried methylene chloride, and 0.88 g of m-dimethoxybenzene and 2.5 ml of trifluoroacetic acid were added to the solution, followed by stirring at room temperature for 4 hours. The solvent was removed by distillation, and the resulting oily residue was subjected to silica gel chromatography to obtain 1.75 g of 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-carboxymethyl-2-azetidinone.


$\text{IR}_{\text{max}}^{\text{neat}}$  ( $\text{cm}^{-1}$ ): ~3000, 1745, 1615, 1510, 1250,  
 1180, 1035

NMR  $\delta$  ( $\text{CDCl}_3$ ): 1.35 (3H, d,  $J=6.5\text{Hz}$ ), 2.35 (2H,

d, J=6.5Hz), 3.10 (1H, m), 3.73 (6H, s), 5.16 (2H, s), 5.75 (1H, s), 6.73 (4H, d, J=9Hz), 7.46 (2H, d, J=9Hz), 8.10 (2H, d, J=9Hz) ppm

Reference Example 9-7

5



0.8 g of 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-carboxymethyl-2-azetidinone was dissolved in 20 ml of dried methylene chloride, and 0.17 ml of N-methylmorpholine was added thereto. After cooling to -10°C or less, 0.15 ml of ethyl chloroformate was added dropwise thereto, followed by stirring for 30 minutes. Separately, 0.81 g of t-butyl-(p-nitrobenzyl) malonate was dissolved in 15 ml of dried tetrahydrofuran, and 0.14 g of sodium hydride (50% purity) was added to the resulting solution in a nitrogen stream under ice-cooling, followed by stirring at that temperature for 30 minutes. The resulting solution was added dropwise to the above prepared solution of a mixed anhydride at a temperature of -10°C

10


15

20

1.9 g of 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-[3-(p-nitrobenzyloxycarbonyl)-2-oxopropyl]-2-azetidinone and 660 mg of p-carboxybenzenesulfonyl azide were dissolved in 50 ml of dried acetonitrile, and 1.4 ml of triethylamine was added thereto dropwise in a nitrogen stream under ice-cooling. After stirring at that temperature for 15 minutes, the reaction mixture was diluted with ethyl acetate, and the thus formed precipitate was filtered. The filtrate was concentrated under reduced pressure, and the resulting oily residue was subjected to silica gel chromatography to obtain 1-(di-p-anisylmethyl)-3-(1-p-nitrobenzyloxycarbonyloxyethyl)-4-[3-(p-nitrobenzyloxycarbonyl)-2-oxo-3-diazopropyl]-2-azetidinone.

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 2150, 1750, 1720 (sh.), 1650, 1510, 1250, 1350

NMR  $\delta$  (CDCl<sub>3</sub>): 1.38 (3H, d, J=6.5Hz), 2.95 (2H, d, J=6.5Hz), 3.73 (6H, s), 5.17 (2H, s), 5.24 (2H, s), 5.74 (1H, s), 6.71 (2H, d, J=9Hz), 6.76 (2H, d, J=9Hz), 7.08 (2H, d, J=9Hz), 7.14 (2H, d, J=9Hz), 7.42 (4H, d, J=9Hz), 8.11 (2H, d, J=9Hz), 8.16 (2H, d, J=9Hz) ppm

Reference Example 9-10

1.27 g 1-(di-p-anisylmethyl)-3-(1-p-nitro-  
benzyloxycarbonyloxyethyl)-4-[3-(p-nitrobenzyloxy-  
5 carbonyl)-2-oxo-3-diazopropyl]-2-azetidinone was  
dissolved in 50 ml of acetonitrile-water (9 : 1 by  
volume), and 2.7 g of ceric ammonium nitrate was added  
thereto all at once under ice-cooling. After vigorous-  
ly stirring, the mixture was further stirred at room  
10 temperature for 30 minutes. Cool water was added to  
the reaction mixture, and the mixture was extracted  
with ethyl acetate. The extract was washed with water  
and dried over sodium sulfate. The solvent was distill-  
ed off, and the resulting residue was purified by silica  
15 gel chromatography to obtain 3-(1-p-nitrobenzyloxy-  
carbonyloxyethyl)-4-[3-(p-nitrobenzyloxycarbonyl)-2-  
oxo-3-diazopropyl]-2-azetidinone.

IR<sup>neat</sup><sub>max</sub> (cm<sup>-1</sup>): 2145, 1750, 1720, 1650, 1520,  
1345, 1260

20 NMR  $\delta$  (CDCl<sub>3</sub>): 1.45 (3H, d, J=6.5Hz), 3.01 (1H,


Isomer (2b)

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1755, 1460, 1377, 1252, 1100,  
835

NMR  $\delta$  (CDCl<sub>3</sub>): 0.06 (6H, s), 0.87 (9H, s),  
1.16 (3H, d, J=6.5Hz), 1.19  
(3H, d, J=7.0Hz), 3.71 (1H,  
dd, J=2 and 10Hz), 5.14 (2H, s),  
7.35 (5H, s) ppm

Isomer (2a)

NMR  $\delta$  (CDCl<sub>3</sub>): 0.06 (6H, s), 0.87 (9H, s), 1.08  
(3H, d, J=6.5Hz), 1.18 (3H, d,  
J=7.0Hz), 3.91 (1H, dd, J=2.2  
and 5.5Hz), 4.17 (2H, q, J=6Hz),  
5.12 (2H, s), 7.35 (5H, s) ppm

Reference Example 10-2


200 mg of 4-(1-benzyloxycarbonyl)ethyl-3-  
[(R)-1-(t-butyl-dimethylsilyloxy)ethyl]-2-  
azetidinone (2a) was dissolved in 2 ml of dried dimethyl-  
formamide. 126 mg of triethylamine was added to the



resulting solution, and then 151 mg of *t*-butyldimethylsilyl chloride was added thereto, followed by stirring at room temperature overnight. The reaction mixture was diluted with ethyl acetate, washed with water, dried over sodium sulfate and purified by silica gel chromatography to obtain 4-(1-benzyloxycarbonyl)ethyl-3-[(*R*)-1-(*t*-butyldimethylsilyloxy)ethyl]-1-(*t*-butyldimethylsilyl)-2-azetidinone (3a).

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1750, 1465, 1325, 1255, 835

Reference Example 10-3



184 mg of 4-(1-benzyloxycarbonyl)ethyl-3-[(*R*)-1-(*t*-butyldimethylsilyloxy)ethyl]-1-(*t*-butyldimethylsilyl)-2-azetidinone (3a) was dissolved in 4 ml of methanol, and the resulting solution was stirred together with 20 mg of 10% palladium-on-carbon at an atmospheric pressure of hydrogen for 2 hours. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure to obtain 4-(1-carboxy)ethyl-3-[(*R*)-1-(*t*-butyldimethylsilyloxy)-

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1740, 1465, 1330, 1255, 1043, 837

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 3450 (br.), 1770 (sh.), 1750,  
1605, 1520, 1350, 1217, 1180


Chemical reaction scheme showing the conversion of a thioether to a sulfoxide. The reactant is a bicyclic molecule with a 4-hydroxy-2-methyl-5-oxo-1,4-dihydro-2H-pyrimidin-2-ylidene group, a 1,3-dithiolane ring, and a COOPNB group. The sulfur atom of the 1,3-dithiolane ring is converted to a sulfoxide group (S=O) in the product.

To a solution of 261 mg of (5R,6S,8R)-p-

nitrobenzyl-3-ethylthio-6-(1-hydroxyethyl)-1-aza-  
bicyclo[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylate in  
28 ml of dried methylene chloride, 144 mg of m-chloro-  
perbenzoic acid was added at  $-45^{\circ}\text{C}$  in a nitrogen stream,  
5 followed by stirring at  $-20^{\circ}$  to  $-40^{\circ}\text{C}$  for 2 hours. The  
reaction mixture was washed with a saturated aqueous  
solution of sodium bicarbonate and then with water,  
dried over sodium sulfate and distilled off to remove  
the solvent. The resulting residue was purified by  
10 silica gel chromatography to obtain (5R,6S,8R)-p-nitro-  
benzyl-3-ethylsulfinyl-6-(1-hydroxyethyl)-1-azabicyclo-  
[3.2.0]hept-2-ene-7-one-4-thia-2-carboxylate.

IR $\nu$   $\text{CHCl}_3$  (cm $^{-1}$ ): 1793, 1703, 1605, 1517, 1447,  
1377, 1344, 1315, 1172, 1112,  
15 1043, 965, 824

NMR  $\delta$  ( $\text{CDCl}_3$ ): 5.74 (3/5H, d,  $J=1.5\text{Hz}$ ), 5.87  
(2/5H, d,  $J=1.5\text{Hz}$ ) ppm

Example 1-1

- a) 122 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate was dissolved in 3 ml of dry acetonitrile, and 31 mg of diisopropylethylamine was added thereto in a nitrogen stream under ice-cooling. Then, 60 mg of [2S,4S]-1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl-4-mercaptopyrrolidine was added to the mixture, followed by stirring for 1 hour. The reaction solution was diluted with ethyl acetate, washed with water, dried over magnesium sulfate and the solvent was distilled off. The residue was purified by silica gel thin layer chromatography to obtain 95 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate.

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1780, 1745, 1705, 1650, 1605, 1515,  
1342, 1257

NMR  $\delta$ (CDCl<sub>3</sub>): 1.49 (3H, d, J=6Hz), 2.99 (3H, s),  
3.11 (3H, s), 5.25 (4H, s), 5.23 and  
5.46 (2H, ABq, J=14Hz), 7.53 (4H, d,  
J=8.5Hz), 7.62 (2H, d, J=8.5Hz),  
8.18 (6H, d, J=8.5Hz)

$[\alpha]_D^{28} +7.7^\circ$  (c=0.303, acetone)


b) 95 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-  
[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)-  
pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-  
1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate was  
dissolved in 20 ml of dioxane, and a morpholinopropane-  
sulfonic acid buffer solution (pH = 7.0, 10 ml) and  
platinum oxide (35 mg) were added thereto. The mixture  
was then hydrogenated under a hydrogen pressure of 3.5 atm.  
for 6.5 hours. The catalyst was filtered off and dioxane  
was distilled off under reduced pressure. The residual  
solution was washed with ethyl acetate, and the aqueous  
layer was again distilled under reduced pressure to remove  
the organic solvent. The residual solution was subjected  
to polymer chromatography (CHP-20P) to obtain (5R,6S,  
8R,2'S,4'S)-3-[4-(2-dimethylaminecarbonyl)pyrrolidinyl-  
thio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-  
7-one-2-carboxylic acid from the fraction eluted with  
water.

UV<sup>H<sub>2</sub>O</sup><sub>max</sub> nm: 297

IR<sup>KBr</sup><sub>max</sub> cm<sup>-1</sup>: 1755, 1627, 1393, 1252, 1130

NMR  $\delta$ (D<sub>2</sub>O): 1.25 (3H, d, J=6.4Hz), 1.81-1.96 (1H, m),  
 2.96 (3H, s), 3.03 (3H, s), 3.14-3.20  
 (3H, m), 3.31-3.41 (2H, m), 3.62-3.72  
 (1H, m), 3.90-4.00 (1H, m), 4.14-4.26  
 (2H, m), 4.63 (1H, t, J=8.5Hz)

Example 1-2



10 a) In the same manner as described in Example 1-1(a)  
 but using 129 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenyl-  
 phosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-  
 1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate and  
 67 mg of [2S,4R]-1-p-nitrobenzyloxycarbonyl-2-dimethyl-  
 15 aminocarbonyl-4-mercaptopyrrolidine, there was obtained  
 40 mg of (5R,6S,8R,2'S,4'R)-p-nitrobenzyl-3-[4-(1-p-  
 nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)pyrrolidinyl-  
 thio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo-  
 [3,2,0]hept-2-ene-7-one-carboxylate.

20 IR<sup>neat</sup><sub>max</sub> (cm<sup>-1</sup>): 1775, 1745, 1705, 1650, 1520, 1400,  
 1345, 1260, 1130

NMR  $\delta$  (CDCl<sub>3</sub>): 1.48 (3H, d, J=6Hz), 2.96 (3H, s),  
 3.12 (3H, s), 5.22 (4H, s), 7.44, 7.50  
 and 7.58 (each 2H, d, J=8.5Hz), 8.17  
 (6H, d, J=8.5Hz)


5       $[\alpha]_D^{27} +31.1^\circ$  (c=0.193, acetone)

b)      In the same manner as described in Example 1-1(b)  
 but using 40 mg of (5R,6S,8R,2'S,4'R)-p-nitrobenzyl-3-  
 [4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)-  
 pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-  
 10      1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate, there  
 was obtained (5R,6S,8R,2'S,4'R)-3-[4-(2-dimethylamine-  
 carbonyl)pyrrolidinylthio]-6-(1-hydroxyethyl)-1-azabicyclo-  
 [3,2,0]hept-2-ene-7-one-2-carboxylic acid.

UV<sub>max</sub><sup>H<sub>2</sub>O</sup> nm: 297

### Example 1-3

15



20

a)      In the same manner as described in Example 1-1(a)  
 but using 61 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenyl-  
 phosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-  
 azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate and 31 mg  
 of [2R,4S]-1-p-nitrobenzyloxycarbonyl-2-dimethylamine-

carbonyl-4-mercaptopyrrolidine, there was obtained 37 mg of (5R,6S,8R,2'R,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate.

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1775, 1745, 1705, 1650, 1520, 1400, 1345, 1260, 1130


NMR  $\delta$ (CDCl<sub>3</sub>): 1.49 (3H, d, J=6.5Hz), 2.98 (3H, s), 3.16 (3H, s), 5.27 (4H, s), 5.19 and 5.47 (2H, ABq, J=14Hz), 7.50, 7.55 and 7.64 (each 2H, d, J=8.5Hz), 8.20 (4H, d, J=8.5Hz), 8.22 (2H, d, J=8.5Hz)

$[\alpha]_D^{29} +26.8^\circ$  (c=0.243, acetone)

b) In the same manner as described in Example 1-1(b) but using 37 mg of (5R,6S,8R,2'R,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate, there was obtained (5R,6S,8R,2'R,4'S)-3-[4-(2-dimethylaminecarbonyl)pyrrolidinylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid.

UV<sub>max</sub><sup>H<sub>2</sub>O</sup> nm: 297



Example 1-4

a) In the same manner as described in Example 1-1(a) but using 76 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate and 39 mg of [2R,4R]-1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl-4-mercaptopyrrolidine, there was obtained 35 mg of (5R,6S,8R,2'R,4'R)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate.

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1775, 1745, 1705, 1650, 1520, 1440, 1342, 1260, 1120


NMR  $\delta$ (CDCl<sub>3</sub>): 1.49 (3H, d, J=6.5Hz), 2.98 (3H, s), 3.09 (3H, s), 5.25 (4H, s), 5.26 and 5.44 (2H, ABq, J=14Hz), 8.20 (6H, d, J=8.5Hz)

$[\alpha]_D^{30} +23.3^\circ$  (c=0.329, acetone)

b) In the same manner as described in Example 1-1(b) but using 35 mg of (5R,6S,8R,2'R,4'R)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl)-pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate, there was obtained (5R,6S,8R,2'R,4'R)-3-[4-(2-dimethylamino-  
 5 carbonyl)pyrrolidinylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid.

UV<sup>H<sub>2</sub>O</sup><sub>max</sub> nm: 297

10

Example 2

a) 53 mg of (4R,5R,6S,8R)-p-nitrobenzyl-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]-hept-3,7-dione-2-carboxylate was dissolved in 5 ml of dry acetonitrile, and 57 mg of diisopropylethylamine and then 43 mg of diphenyl chlorophosphate were added thereto. After stirring for 2.5 hours, 57 mg of [2S,4S]-1-p-nitrobenzyloxycarbonyl-2-dimethylaminocarbonyl-4-mercaptopyrrolidine was added to the mixture, followed by stirring for 1 hour. The reaction solution was diluted with ethyl acetate, washed with water, dried over magnesium sulfate and the solvent was distilled off. The residue was purified by silica gel thin layer chromatography to obtain 35 mg of (4R,5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)pyrrolidinylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate.

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1760, 1705, 1645, 1520, 1402, 1342, 1135, 1110

NMR  $\delta$ (CDCl<sub>3</sub>): 1.30 (3H, d, J=7.0Hz), 1.35 (3H, d, J=6.5Hz), 2.99 (3H, s), 3.02 (3H, d, J=15Hz), 5.21 (2H, s), 5.20 and 5.43 (2H, ABq, J=14Hz), 7.51 (2H, d, J=8.5Hz), 7.64 (2H, d, J=8.5Hz), 8.20 (4H, d, J=8.5Hz)


b) 25 mg of (4R,5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)-pyrrolidinylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate was dissolved in  
5 a mixture of 1.9 ml of tetrahydrofuran and 0.3 ml of ethanol, and the mixture was hydrogenated in a morpholino-propanesulfonic acid buffer solution (pH = 7.0, 1.9 ml) under atmospheric pressure of hydrogen for 3 hours at room temperature in the presence of 30 mg of 10% palladium-  
10 carbon, which had been activated in hydrogen atmosphere for 1 hour followed by washing with water.  
After filtering off the catalyst, tetrahydrofuran and ethanol were distilled off under reduced pressure, and the residual solution was washed with ethyl acetate.  
15 The aqueous layer was again distilled under reduced pressure to remove organic solvents, and the residual solution was subjected to polymer chromatography (CHP-20P) to obtain (4R,5R,6S,8R,2'S,4'S)-3-[4-(2-dimethylamine-carbonyl)pyrrolidinylthio]-4-methyl-6-(1-hydroxyethyl)-  
20 1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid from the fraction eluted with water.

UV<sup>H<sub>2</sub>O</sup><sub>max</sub> nm: 296

NMR  $\delta$  ( $D_2O$ ): 1.21 (3H, d,  $J=7.0\text{Hz}$ ), 1.29 (3H, d,  $J=6.5\text{Hz}$ ), 1.92 (1H, m), 2.99 (3H, s), 3.06 (3H, s)

Example 3

5



a) 61 mg of (4R,5R,6S,8R)-p-nitrobenzyl-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]-hept-3,7-dione-2-carboxylate was dissolved in 6 ml of dry acetonitrile, and 72 mg of diisopropylethylamine and then 55 mg of diphenyl chlorophosphate were added thereto in a nitrogen stream under ice-cooling, followed by stirring for 2.5 hours. 77 mg of [2S,4S]-1-p-nitrobenzyloxycarbonyl-2-(1-pyrrolidinecarboxyl)-4-mercaptopyrrolidine was added to the mixture, followed by stirring for 1 hour. The reaction solution was diluted with ethyl acetate, washed with water, dried over magnesium sulfate, and the solvent was distilled off. The residue was purified by silica gel thin layer chromatography to obtain 51 mg of (4R,5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[(1-p-nitrobenzyloxycarbonyl)-2-(1-pyrrolidinecarboxyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-

10

15

20

one-2-carboxylate.

IR<sub>max</sub><sup>neat</sup> (cm<sup>-1</sup>): 1760, 1710, 1640, 1525, 1440, 1350,  
1210, 1110

5 NMR  $\delta$  (CDCl<sub>3</sub>) : 1.30 (3H, d, J=7.0Hz), 1.34 (3H, d,  
J=6.5Hz), 5.21 (2H, s), 5.20 and 5.44  
(2H, ABq, J=14Hz), 7.50 (2H, d, J=8.5Hz)  
7.64 (2H, d, J=8.5Hz), 8.20 (4H, d,  
J=8.5Hz)


b) 50 mg of (4R,5R,6S,8R,2'S,4'S)-p-nitrobenzyl-  
10 3-[1-p-nitrobenzyloxycarbonyl-2-(1-pyrrolidinecarbonyl)-  
pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-  
azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate was  
dissolved in a mixture of 3.9 ml of tetrahydrofuran and  
0.6 ml of ethanol, and the mixture was hydrogenated in a  
15 morpholinopropanesulfonic acid buffer solution (pH = 7.0,  
3.9 ml) under atmospheric pressure of hydrogen for 4.5 hours  
at room temperature in the presence of 60 mg of 10% pal-  
ladium-carbon, which had been activated in hydrogen  
atmosphere for 1 hour followed by washing with water.  
20 After filtering off the catalyst, tetrahydrofuran  
and ethanol were distilled off under reduced pressure,  
and the residual solution was washed with ethyl  
acetate. The aqueous layer was again distilled under  
reduced pressure to remove organic solvents, and the

residual solution was subjected to polymer chromatography (CHP-20P) to obtain (4R,5R,6S,8R,2'S,4'S)-3-[2-(1-pyrrolidinecarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylic acid from the fraction eluted with a 2% aqueous tetrahydrofuran solution.

UV<sup>H<sub>2</sub>O</sup><sub>max</sub> nm : 297

NMR  $\delta$ (D<sub>2</sub>O); 1.20 (3H, d, J=7.0Hz), 1.28 (3H, d, J=6.5Hz), 1.95 (6H, m), 3.46 (6H, m), 3.72 (1H, dd, J=6.5 and 12Hz), 4.02 (1H, quintet, J=6.5Hz)

#### Example 4



a) 172 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate was dissolved in 2.3 ml of dry acetonitrile, and to the solution were added a solution of 59 mg of diisopropylethylamine in 0.7 ml of dry acetonitrile and then a solution of 94 mg of [2S,4S]-1-p-nitrobenzyloxycarbonyl-2-(3-pyrroline-1-carbonyl)-4-mercaptopyrrolidine in 1 ml of dry aceto-

nitride, in a nitrogen stream and under ice-cooling,  
 followed by stirring for 15 minutes. The reaction  
 solution was diluted with diethyl ether, washed with  
 water, and the insoluble material in the ether layer  
 5 was dissolved with addition of methylene chloride.  
 The methylene chloride and ether layer was dried over  
 magnesium sulfate and the solvent was distilled off.  
 The residue was purified by silica gel thin layer chromato-  
 graphy to obtain 182 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-  
 10 3-{4-[1-p-nitrobenzyloxycarbonyl-2-(3-pyrroline-1-carbonyl)]-  
 pyrrolidinylthio}-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-  
 1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-carboxylate.

IR<sup>CHCl<sub>3</sub></sup><sub>max</sub> (cm<sup>-1</sup>): 1780, 1745, 1708, 1660, 1623, 1606,  
 1520, 1342

15 NMR  $\delta$  (CDCl<sub>3</sub>): 1.49 (3H, d, J=6.2Hz), 5.26 (4H, s),  
 8.18 (6H, d, J=8.8Hz)

b) 182 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-  
 3-{4-[1-p-nitrobenzyloxycarbonyl-2-(3-pyrroline-1-  
 carbonyl)]pyrrolidinylthio}-6-(1-p-nitrobenzyloxycarbonyl-  
 20 oxyethyl)-1-azabicyclo[3,2,0]-hept-2-ene-7-one-2-  
 carboxylate was dissolved in a mixture of 12.6 ml of  
 tetrahydrofuran and 2 ml of ethanol, and the solution was  
 hydrogenated in a morpholinopropane-  
 sulfonic acid buffer solution (pH = 7.0, 12.6 ml)  
 25 at room temperature under atmospheric pressure of hydrogen




for 7 hours in the presence of 219 mg of 10% palladium-carbon, which had been activated in hydrogen atmosphere for 1 hour, followed by washing with water. After filtering off the catalyst, tetrahydrofuran and ethanol were distilled off under reduced pressure, and the residual solution was washed with ethyl acetate. The aqueous layer was again distilled under reduced pressure to remove organic solvents, and the residual solution was subjected to polymer chromatography (CHP-20P) to obtain (5R,6S,8R,2'S,4'S)-3-{4-[2-(3-pyrroline-1-carbonyl)pyrrolidinylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid from the fraction eluted with a 2% aqueous tetrahydrofuran solution.

15           UV  $\lambda_{\text{max}}^{\text{H}_2\text{O}}$  nm: 298

IR  $\text{KBr}_{\text{max}}$  ( $\text{cm}^{-1}$ ): 1755, 1640, 1595, 1450, 1380, 1245

NMR  $\delta$  ( $\text{D}_2\text{O}$ ): 1.26 (3H, d,  $J=6.4\text{Hz}$ ), 3.18 (1H, dd,  $J=2.1$  and  $9.0\text{Hz}$ ), 3.77 (1H, dd,  $J=7.0$  and  $12.0\text{Hz}$ ), 5.89 (2H, br. s)

Example 5

a) Following the procedures as described in Example 1-1(a) using 68 mg of (5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy)-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate and 33 mg of [2S,4S]-1-p-nitrobenzyloxycarbonyl-2-carbamoylmethylaminecarbonyl-4-mercaptopyrrolidine, there was obtained 61 mg of crystalline (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-carbamoylmethylaminecarbonyl)pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate by filtration.

IR<sub>max</sub><sup>Nujol</sup> (cm<sup>-1</sup>): 3445, 3300, 1790, 1745, 1710, 1670, 1635, 1510, 1345, 1270

NMR  $\delta$  (CDCl<sub>3</sub>): 1.50 (3H, d, J=6.5Hz), 5.23 (4H, s), 7.50 (4H, d, J=8.5Hz), 8.21 (6H, d, J=8.5Hz)

m.p.: 184-189°C (dec.)


b) 30 mg of (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[4-(1-p-nitrobenzyloxycarbonyl-2-carbamoylmethylamine-carbonyl)pyrrolidinylthio]-6-(1-p-nitrobenzyloxycarbonyloxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylate  
5 was dissolved in a mixture of 3.1 ml of tetrahydrofuran and 1 ml of dimethylformamide, and the solution was hydrogenated in the presence of a morpholinopropane-sulfonic acid buffer solution (pH = 7.0, 3.1 ml) at room temperature under atmospheric pressure of hydrogen  
10 for 5 hours in the presence of 37 mg of 10% palladium-carbon which had been activated in hydrogen atmosphere for 1 hour followed by washing with water. After filtering off the catalyst, tetrahydrofuran was distilled off under reduced pressure, and the residual solution was  
15 washed with methylene chloride. The aqueous layer was distilled to remove the organic solvents, and the residual solution was subjected to polymer chromatography (CHP-20P) to obtain (5R,6S,8R,2'S,4'S)-3-[4-(2-carbamoylmethylaminecarbonyl)pyrrolidinylthio]-6-(1-hydroxyethyl)-  
20 1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid from the fraction eluted with water.

UV  $\lambda_{\text{max}}^{\text{H}_2\text{O}}$  nm: 300

IR  $\lambda_{\text{max}}^{\text{KBr}}$  ( $\text{cm}^{-1}$ ): 1745, 1665, 1590, 1390, 1220, 1180, 1040

NMR  $\delta$ (D<sub>2</sub>O): 1.26 (3H, d, J=6.6Hz), 1.86 (1H, m),  
 3.20 (2H, dd, J=7.5 and 14.7Hz), 3.38  
 (1H, dd, J=3.0 and 6.7Hz), 4.02 (1H, t,  
 J=9.0Hz)

5

Example 6

a) To a solution of 45 mg of (5R,6S,8R)-p-nitrobenzyl-3-ethylsulfinyl-6-(1-hydroxyethyl)-1-azabicyclo-[3,2,0]hept-2-ene-7-one-4-thia-2-carboxylate in 0.8 ml  
 10 of dry acetonitrile were added a solution of 30 mg of diisopropylethylamine in 0.3 ml of dry acetonitrile and then a solution of 81 mg of (2'S,4'S)-1'-p-nitrobenzyl-oxycarbonyl-2-dimethylaminocarbonyl-4'-mercaptopyrrolidine in 0.6 ml of dry acetonitrile under nitrogen stream at  
 15 -40°C, followed by stirring the mixture at -40°C to -45°C for 10 minutes. The reaction solution was diluted with ethyl acetate, washed with a saturated aqueous solution of sodium chloride, dried over sodium sulfate, and the solvent was distilled off. The resulting residue was  
 20 purified by silica gel chromatography to obtain (5R,6S,8R,2'S,4'S)-p-nitrobenzyl-3-[(1-p-nitrobenzyloxycarbonyl-

2-dimethylaminecarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxy-ethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-4-thia-2-carboxylate.

$$[\alpha]_D^{29} +52^\circ \quad (c=0.43, \text{CHCl}_3)$$

5 IR  $\nu_{\text{max}}^{\text{CHCl}_3}$  ( $\text{cm}^{-1}$ ): 1788, 1700, 1660, 1607, 1400, 1325, 1114, 1013

NMR  $\delta$  ( $\text{CDCl}_3$ ): 1.32 (3H, d,  $J=6\text{Hz}$ ), 2.96 (3H, s),  
3.08 (3H, s), 3.72 (1H, dd,  $J=1.5\text{Hz}$   
and  $J=6\text{Hz}$ ), 5.20 (2H, s), 5.70 (1H, d,  
10  $J=1.5\text{Hz}$ )

b) 204 mg of 5% palladium-carbon was suspended in a mixture of ethanol (3.8 ml) and water (3.8 ml) and hydrogenated at room temperature under atmospheric pressure for 1 hour. The catalyst was filtered, washed  
15 with water, suspended in a phosphate buffer (pH = 6.86, 5.1 ml); and added to a solution of 68 mg of (5R,6S,8R, 2'S,4'S)-p-nitrobenzyl-3-[(1-p-nitrobenzyloxycarbonyl-2-dimethylaminecarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxy-ethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-4-thia-2-  
20 carboxylate in 7.7 ml of tetrahydrofuran. The mixture was hydrogenated at room temperature and under atmospheric pressure for 3 hours. After filtering off the catalyst, tetrahydrofuran was distilled off under reduced pressure.

The residual solution was washed with ethyl acetate, and the aqueous layer was again distilled under reduced pressure to remove the organic solvents. The resulting residual solution was purified by CHP-20P column

- 5 chromatography to obtain (5R,6S,8R,2'S,4'S)-2-[(2-dimethyl-aminecarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-4-thia-2-carboxylic acid.

UV  $\lambda_{\text{max}}^{\text{H}_2\text{O}}$  nm: 322, 255

10 IR  $\nu_{\text{max}}^{\text{KBr}}$  ( $\text{cm}^{-1}$ ): 1765, 1645, 1580, 1508, 1367


NMR  $\delta$  ( $\text{D}_2\text{O}$ ): 1.29 (3H, d,  $J=6.4\text{Hz}$ ), 1.94 - 2.08 (1H, m), 2.93 - 3.15 (1H, m), 2.98 (3H, s), 3.05 (3H, s), 3.53-3.62 (1H, m), 3.83 - 3.93 (1H, m), 3.94 (1H, dd,  $J=1.4\text{Hz}$  and  $J=6\text{Hz}$ ), 4.06 - 4.30 (3H, m), 15 5.71 (1H, d,  $J=1.4\text{Hz}$ )

#### Examples 7 to 90





The compounds shown in Table 6 below were prepared from the corresponding mercaptan derivatives.

- 20 In Table 6, "HE" represents (R)-1-hydroxyethyl group, and "PNZE" represents (R)-1-p-nitrobenzyloxycarbonyloxy-ethyl group.

Table 6



Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
					IR <sub>Nujol</sub> (cm <sup>-1</sup> ): 3420, 1785, 1742, 1710, 1677, 1510, max 1342, 1255 m.p. 138-142°C [α] <sub>D</sub> <sup>30</sup> +44.4° (c=0.105, DMF) UV <sub>max</sub> <sup>H<sub>2</sub>O</sup> nm: 297
					IR <sub>KBr</sub> (cm <sup>-1</sup> ): 1752, 1687, 1595, 1385 NMR δ (D <sub>2</sub> O): 1.24(3H, d, J=6.5Hz), 2.0-2.15(1H, m), 2.83-2.98(1H, m), 3.17(2H, d, J=9Hz), 3.32-3.42(2H, m), 3.71-3.80(1H, m), 3.98(1H, quintet, J=7Hz), 4.13-4.32(1H, m), 4.41(1H, m, J=8.5Hz)
					[α] <sub>D</sub> <sup>30</sup> -25° (c=0.05, H <sub>2</sub> O)

sample no.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
8	PNZE	PNZ	PNB		IR ν <sub>max</sub> (cm <sup>-1</sup> ): 1775, 1745, 1700, 1665(sh), 1515, 1345, 1257  NMR δ(CDCl <sub>3</sub> ): 1.48(3H, d, J=6.5Hz), 2.73(3H, s), 3.21(2H, d, J=9Hz), 5.25(4H, s), 5.25 and 5.43(2H, ABq, J=14Hz), 7.50, 7.54 and 7.62(each 2H, d, J=8.5Hz), 8.20(6H, d, J=8.5Hz)
	HE	H	H		UV λ <sub>max</sub> H <sub>2</sub> O nm: 297
9	PNZE	PNZ	PNB		IR ν <sub>max</sub> Nujol (cm <sup>-1</sup> ): 1770, 1740, 1700, 1510, 1340, 1255  NMR δ(CDCl <sub>3</sub> ): 1.08(3H, d, J=6.5Hz), 1.11(3H, d, J=6.5Hz), 1.48(3H, d, J=6Hz), 3.18(2H, br.d, J=9Hz), 5.25(4H, s), 5.26 and 5.44(2H, ABq, J=14Hz), 7.50, 7.54 and 7.62(each 2H, J=9Hz), 8.20(6H, d, J=8.5Hz)
	HE	H	H		UV λ <sub>max</sub> H <sub>2</sub> O nm: 296




Sample No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{CH}=\text{CH}_2 \\   \\ \text{-N-} \end{array}$	IR $\nu_{\text{max}}$ Nujol (cm <sup>-1</sup> ): 3275, 1782, 1740, 1700, 1650, 1515, 1340, 1260  NMR $\delta$ (CDCl <sub>3</sub> ): 1.48(3H, d, J=6.5Hz), 3.18(2H, br, d, J=9Hz), 5.24(4H, s), 5.25 and 5.45(2H, ABq, J=14Hz), 7.50, 7.53 and 7.62(each 2H, d, J=8.5Hz), 8.19(6H, d, J=8.5Hz)
	HE	H	H	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3 \\   \\ \text{-N-} \end{array}$	NMR $\delta$ (D <sub>2</sub> O): 1.0(3H, t, J=7.5Hz), 1.23(3H, d, J=7Hz)  UV $\lambda_{\text{max}}$ H <sub>2</sub> O nm: 298
	HE	H	H	$\begin{array}{c} \text{CH}_2\text{CH}=\text{CH}_2 \\   \\ \text{-N-} \end{array}$	NMR $\delta$ (D <sub>2</sub> O): 1.27(3H, d, J=7Hz), 5.68(3H, m)  UV $\lambda_{\text{max}}$ H <sub>2</sub> O nm: 298

Example  
No.

R<sub>1</sub> R<sub>2</sub> R<sub>3</sub> Y


Spectral Data

IR ν<sub>neat</sub> (cm<sup>-1</sup>): 1780, 1750, 1710, 1650, 1525, 1440, 1350, 1262




NMR δ (CDCl<sub>3</sub>): 1.06(3H, t, J=7Hz), 1.27(3H, t, J=7Hz), 1.49(3H, d, J=6Hz), 5.24(4H, s), 5.25 and 5.46(2H, ABq, J=14Hz), 7.46, 7.50 and 7.63(each 2H, d, J=8.5Hz), 8.20(6H, d, J=8.5Hz)

11




UV λ<sub>H<sub>2</sub>O</sub> nm: 297



IR ν<sub>CHCl<sub>3</sub></sub> (cm<sup>-1</sup>): 1780, 1746, 1708, 1656, 1610, 1525, 1350, 1260

NMR δ (CDCl<sub>3</sub>): 1.48(3H, d, J=6Hz), 5.27(4H, s), 8.20(6H, d, J=9Hz)

12



IR ν<sub>KBr</sub> (cm<sup>-1</sup>): 1755, 1635, 1590, 1370, 1240

NMR δ (D<sub>2</sub>O): 0.88(3H, t, J=7.1Hz), 1.26(3H, d, J=6.4Hz), 1.91(1H, m), 2.94 and 3.02(2H, m)

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data	
13	PNZE	H	PNB	$\begin{array}{c} \text{CH}_2\text{Ph} \\ \diagup \quad \diagdown \\ -\text{N} \quad \text{H} \end{array}$	IR $\nu_{\text{max}}$ Nujol (cm <sup>-1</sup> ): 1770, 1735, 1640, 1510, 1340, 1250  NMR $\delta$ (CDCl <sub>3</sub> ): 1.49(3H, d, J=6.5Hz), 4.42(2H, J=7.0Hz), 5.25(4H, s), 5.27 and 5.43(2H, ABq, J=14Hz), 7.27(5H, s), 7.54, 7.62, 8.21 and 8.22(each 2H, d, J=8.5Hz)	UV $\lambda_{\text{max}}$ H <sub>2</sub> O nm: 297
14	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{Ph} \\ \diagup \quad \diagdown \\ -\text{N} \quad \text{CH}_3 \end{array}$	IR $\nu_{\text{max}}$ neat (cm <sup>-1</sup> ): 1780, 1750, 1715, 1660, 1525, 1442, 1350, 1265, 1122  NMR $\delta$ (CDCl <sub>3</sub> ): 1.48(3H, d, J=6.5Hz), 2.92(3H, s), 4.56(2H, d, J=5Hz), 5.25(4H, s), 8.19(6H, d, J=9Hz)	UV $\lambda_{\text{max}}$ H <sub>2</sub> O nm: 297

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
18	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{OH} \\   \\ \text{--N--} \\   \\ \text{H} \end{array}$	<p>IR <math>\nu_{\text{max}}^{\text{neat}}</math> (cm<sup>-1</sup>): 3350, 1770, 1740, 1695, 1510, 1340, 1250</p> <p>NMR <math>\delta</math> (CDCl<sub>3</sub>): 1.48(3H, d, J=6Hz), 5.25(4H, s), 5.18 and 5.43(2H, ABq, J=14Hz), 7.49, 7.53 and 7.61(each 2H, d, J=8.5Hz), 8.18(6H, d, J=8.5Hz)</p> <p>UV <math>\lambda_{\text{max}}^{\text{H}_2\text{O}}</math> nm: 298</p>
19	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{OH} \\   \\ \text{--N--} \\   \\ \text{CH}_3 \end{array}$	<p>IR <math>\nu_{\text{max}}^{\text{neat}}</math> (cm<sup>-1</sup>): 3400, 1778, 1745, 1700, 1650, 1520, 1345, 1260, 1120</p> <p>NMR <math>\delta</math> (CDCl<sub>3</sub>): 1.48(3H, d, J=6.5Hz), 3.00(3H, s), 5.20(2H, s), 5.25(2H, s), 5.25 and 5.45(2H, ABq, J=13.5Hz), 7.49, 7.51 and 7.63(each 2H, d, J=8.5Hz), 8.19(4H, d, J=8.5Hz), 8.21(2H, d, J=8.5Hz)</p> <p>UV <math>\lambda_{\text{max}}^{\text{H}_2\text{O}}</math> nm: 297</p>

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
20	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{CH}_2\text{COOPNB} \\   \\ \text{---N---} \\   \\ \text{H} \end{array}$	IR ν <sub>max</sub> (neat) (cm <sup>-1</sup> ): 1770, 1730, 1695, 1650, 1600, 1505, 1340  NMR δ (CDCl <sub>3</sub> ): 1.48(3H, d, J=6.5Hz), 5.25(4H, s), 7.62(2H, d, J=8.6Hz), 8.20(6H, d, J=8.6Hz)
	HE	H	H	$\begin{array}{c} \text{CH}_2\text{CH}_2\text{CH}_2\text{COOH} \\   \\ \text{---N---} \\   \\ \text{H} \end{array}$	UV λ <sub>max</sub> <sup>H<sub>2</sub>O</sup> nm: 297
	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{CONHCH}_3 \\   \\ \text{---N---} \\   \\ \text{H} \end{array}$	IR ν <sub>max</sub> Nujol (cm <sup>-1</sup> ): 1795, 1747, 1712, 1640, 1608, 1517, 1350, 1275  m.p. 167-169°C (dec.)
21	HE	H	H	$\begin{array}{c} \text{CH}_2\text{CONHCH}_3 \\   \\ \text{---N---} \\   \\ \text{H} \end{array}$	IR ν <sub>max</sub> KBr (cm <sup>-1</sup> ): 1752, 1650, 1590, 1388, 1255, 1150  NMR δ (D <sub>2</sub> O): 1.26(3H, d, J=6.3Hz), 2.71(3H, s), 2.93(1H, q, J=7.4Hz), 3.88(2H, s)

Example  
No.

R<sub>1</sub> R<sub>2</sub> R<sub>3</sub>

Y

Spectral Data



PNZE PNZ PNB

IR<sub>Nujol</sub> (cm<sup>-1</sup>): 1800, 1750, 1707, 1675, 1650, 1610, 1520, 1350, 1280

m.p. 196-199°C (dec.)

UV $\lambda$  H<sub>2</sub>O nm: 299




HE H H

IR<sub>KBr</sub> (cm<sup>-1</sup>): 1750, 1640, 1590, 1380, 1250, 1145

NMR $\delta$  (D<sub>2</sub>O):


1.26(3H, d, J=6.3Hz), 2.92(3H, s),  
3.03(3H, s), 3.19(2H, dd, J=6.3 and  
9.2Hz), 3.51(1H, dd, J=7.4 and 12Hz),  
4.12(2H, s)



PNZE PNZ PNB

IR<sub>Nujol</sub> (cm<sup>-1</sup>): 1795, 1750, 1700, 1680, 1655, 1610, 1525, 1350

m.p. 168-170°C (dec.)



HE H H

IR<sub>KBr</sub> (cm<sup>-1</sup>): 1745, 1665, 1590, 1390, 1180, 1037

UV $\lambda$  H<sub>2</sub>O nm: 299

Example  
No.

R<sub>1</sub>


R<sub>2</sub>

R<sub>3</sub>

Y

Spectral Data

PNZE PNZ PNB




IR<sub>Nujol</sub> (cm<sup>-1</sup>): 1790, 1752, 1710, 1650, 1610, 1525,  
max 1350

m.p. 98-101°C

24

UV<sub>H<sub>2</sub>O</sub> nm: 301  
max



HE

H

H

IR<sub>KBr</sub> (cm<sup>-1</sup>): 1750, 1650, 1590, 1385, 1170, 1040  
max

NMR<sub>δ</sub> (D<sub>2</sub>O):

1.26(3H, d, J=6.6Hz), 1.36(3H, d,  
J=8.1Hz), 2.71(3H, s), 3.19(1H, dd,  
J=6.6 and 9.0Hz), 3.98(1H, t,  
J=8.0Hz)

Example  
No.


R<sub>1</sub>

R<sub>2</sub>

R<sub>3</sub>

Y

Spectral Data




IR<sub>v</sub><sup>neat</sup> (cm<sup>-1</sup>): 1780, 1745, 1705, 1640, 1605, 1520,  
1346

m.p. 172-175°C

NMR $\delta$  (D<sub>6</sub>-DMCO): 1.12(3H, d, J=7Hz), 1.34(3H, d,  
J=6.4Hz), 2.79(3H, s), 2.94(3H, s),  
5.30(2H, s), 8.20(6H, d, J=8.8Hz)

25

UV $\lambda$ <sub>max</sub><sup>H<sub>2</sub>O</sup> nm: 300



IR<sub>v</sub><sup>KBr</sup> (cm<sup>-1</sup>): 1755, 1630, 1590, 1390, 1250, 1120

NMR $\delta$  (D<sub>2</sub>O): 1.26(3H, d, J=6.3Hz), 1.31(3H, d,  
J=6.9Hz), 2.92(3H, s), 3.13(3H, s)



Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
	PNZE	PNZ	PNB	$\begin{array}{c} \text{CH}_2\text{CONH}_2 \\ \diagup \quad \diagdown \\ -\text{N} \quad \text{CH}_3 \end{array}$	IR $\nu_{\text{max}}$ $\text{CHCl}_3$ ( $\text{cm}^{-1}$ ): 1783, 1746, 1705, 1680, 1608, 1524, 1345  NMR $\delta$ ( $\text{CDCl}_3$ ): 1.48(3H, d, J=6.4Hz), 3.19(3H, s), 5.17(2H, s), 5.24(2H, s), 8.19(6H, d, J=8.6Hz)
26	HE	H	H	$\begin{array}{c} \text{CH}_2\text{CONH}_2 \\ \diagup \quad \diagdown \\ -\text{N} \quad \text{CH}_3 \end{array}$	UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 300  IR $\nu_{\text{max}}^{\text{KBr}}$ ( $\text{cm}^{-1}$ ): 1750, 1654, 1590, 1395, 1250, 1060  NMR $\delta$ ( $\text{D}_2\text{O}$ ): 1.26(3H, d, J=6.3Hz), 2.95(3H, s), 3.21(2H, dd, J=2.2 and 9.0Hz), 3.38(1H, dd, J=2.2 and 5.5Hz)

Example  
No.

R<sub>1</sub>


R<sub>2</sub>

R<sub>3</sub>

Y

Spectral Data

IR ν<sub>max</sub> CHCl<sub>3</sub> (cm<sup>-1</sup>): 1778, 1743, 1685, 1660, 1605, 1520, 1340




PNZE PNZ PNB

NMR δ (CDCl<sub>3</sub>): 1.48(3H, d, J=6.2Hz), 2.72(3H, d, J=5Hz), 3.19(3H, s), 5.22(2H, s), 5.25(2H, s), 8.22(6H, d, J=8.8Hz)

27

UV λ<sub>max</sub> H<sub>2</sub>O nm: 300



HE H H

IR ν<sub>max</sub> KBr (cm<sup>-1</sup>): 1750, 1640, 1585, 1382, 1250, 1125

NMR δ (D<sub>2</sub>O): 1.26(3H, d, J=6.3Hz), 2.73(3H, s), 3.09(3H, s), 3.39(1H, q, J=2.6Hz)

Example

No.

R<sub>1</sub>


R<sub>2</sub>

R<sub>3</sub>

Y

Spectral Data

IR<sub>ν</sub>neat (cm<sup>-1</sup>): 1778, 1745, 1705, 1650, 1605, 1520, 1345



PNZE PNZ PNB

NMRδ (CDCl<sub>3</sub>): 1.49(3H, d, J=6.2Hz), 2.93(3H, s), 2.99(3H, s), 3.10 and 3.15(3H, s), 5.25(4H, s), 8.21(6H, d, J=8.4Hz)

28

UVλ<sub>H<sub>2</sub>O</sub> nm: 297





HE




H



H





IR<sub>ν</sub>KBr (cm<sup>-1</sup>): 1760, 1650, 1500, 1380, 1240, 1130

0126587

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
29	PNZE	PNZ	PNB		<p>IR ν<sub>max</sub> (cm<sup>-1</sup>): 1778, 1750, 1705, 1650, 1518, 1430, 1345, 1258</p> <p>NMR δ (CDCl<sub>3</sub>): 1.49(3H, d, J=6.5Hz), 2.25(3H, s), 2.31(4H, s), 5.25(4H, s), 5.21 and 5.46(2H, ABq, J=13.5Hz), 7.53(4H, d, J=8.5Hz), 7.62(2H, d, J=8.5Hz), 8.20(6H, d, J=8.5Hz)</p> <p>UV λ<sub>H<sub>2</sub>O</sub> max nm: 298</p>
30	PNZE	PNZ	PNB		<p>IR ν<sub>max</sub> (cm<sup>-1</sup>): 1780, 1750, 1710, 1655, 1520, 1350, 1255, 1115</p> <p>NMR δ (CDCl<sub>3</sub>): 1.48(3H, d, J=6.5Hz), 3.58 and 3.67(each 4H, s), 5.25(4H, s), 5.26 and 5.45(2H, ABq, J=14Hz), 7.53(4H, d, J=9Hz), 7.62(2H, d, J=9Hz), 8.19(6H, d, J=9Hz)</p> <p>UV λ<sub>H<sub>2</sub>O</sub> max nm: 298</p>

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
31	PNZE	PNZ	PNB		<p>IR <math>\nu_{\text{max}}</math> CHCl<sub>3</sub> (cm<sup>-1</sup>): 1780, 1740, 1705, 1655, 1610, 1520, 1345</p> <p>NMR <math>\delta</math> (CDC<sub>3</sub>): 1.47(3H, d, J=6Hz), 5.22(4H, s), 8.13(6H, d, J=8Hz)</p> <p>UV <math>\lambda_{\text{max}}</math> H<sub>2</sub>O nm: 298</p> <p>IR <math>\nu_{\text{max}}</math> KBr (cm<sup>-1</sup>): 1750, 1625, 1595, 1396, 1248, 1090</p> <p>IR <math>\nu_{\text{max}}</math> neat (cm<sup>-1</sup>): 1780, 1740, 1700, 1590, 1520, 1340, 1255</p> <p>NMR <math>\delta</math> (CDC<sub>3</sub>): 1.49(3H, d, J=6.6Hz), 5.26(4H, s), 5.35(2H, ABq, J=14.5Hz), 7.46(2H, d, J=5.5Hz), 8.48(2H, d, J=5.5Hz)</p> <p>UV <math>\lambda_{\text{max}}</math> H<sub>2</sub>O nm: 245, 300</p> <p>IR <math>\nu_{\text{max}}</math> (cm<sup>-1</sup>): 1745, 1690, 1590, 1507, 1383, 1285</p>
32	PNZE	PNZ	PNB		
	HE	H	H		

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
	PNZE	PNZ	PNB		<p>IR, Nujol (cm<sup>-1</sup>): 1785, 1745, 1705, 1605, 1520, 1350  max  m.p. 181-183°C (dec.)</p> <p>UV, H<sub>2</sub>O nm:  max 296, 276, 231</p> <p>IR, KBr (cm<sup>-1</sup>): 1750, 1690, 1595, 1435, 1385, 1240,  max 1090</p> <p>NMR δ (D<sub>2</sub>O):  1.26(3H, d, J=6.3Hz), 1.95(1H, m),  3.20(1H, dd, J=4.0 and 9.0Hz),  3.37(1H, dd, J=2.6 and 6.1Hz),  8.32(1H, dd, J=1.3 and 5.0Hz),  8.60(1H, d, J=2.2Hz)</p>
33	HE	H	H		

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
34	PNZE	PNZ	PNB		IR <sup>Nujol</sup> (cm <sup>-1</sup> ): 1790, 1745, 1705, 1670, 1605, 1515, 1345 m.p. 189-191°C (dec.)
					UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 298, 286, 237
	HE	H	H		IR <sup>KBr</sup> (cm <sup>-1</sup> ): 1750, 1680, 1590, 1480, 1390, 1245, 1090
					NMR $\delta$ (D <sub>2</sub> O): 1.26(3H, d, J=6.3Hz), 1.95(1H, m), 3.20(1H, dd, J=4.0 and 9.0Hz), 3.37(1H, dd, J=2.6 and 6.1Hz), 8.32(1H, dd, J=1.3 and 4.9Hz), 8.60(1H, d, J=2.2Hz)
35	PNZE	PNZ	PNB		IR <sup>neat</sup> (cm <sup>-1</sup> ): 1775, 1750, 1705, 1640, 1520, 1345, 1255, 1110
					NMR $\delta$ (CDCl <sub>3</sub> ): 1.48(3H, d, J=6.5Hz), 5.24(4H, s), 5.23 and 5.44(2H, ABq, J=14Hz), 8.19(6H, d, J=8.5Hz)
	HE	H	H		UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 297

Example  
No.R<sub>1</sub> R<sub>2</sub> R<sub>3</sub>

Y

Spectral Data

IR  $\nu_{\text{max}}$  (neat  $\text{cm}^{-1}$ ): 1782, 1750, 1710, 1660, 1522, 1445, 1355, 1270, 1140

PNZE PNZ PNB

-N

NMR  $\delta$  (CDC <sub>3</sub>):

1.48(3H, d, J=6Hz), 5.26(4H, s),  
5.18 and 5.42(2H, ABq, J=14Hz),  
7.50(2H, d, J=8.5Hz), 7.53(2H, d,  
J=8.5Hz), 7.62(2H, d, J=8.5Hz),  
8.19(6H, d, J=8.5Hz)

36

UV  $\lambda_{\text{max}}$   $\text{H}_2\text{O}$  nm: 298

HE H H



-N



IR  $\nu_{\text{max}}$  (KBr  $\text{cm}^{-1}$ ): 1755, 1630, 1600, 1440, 1382, 1240

NMR  $\delta$  ( $\text{D}_2\text{O}$ ):

1.26(3H, d, J=6.3Hz), 2.34(2H, m),  
3.36(1H, dd, J=3.4 and 5.5Hz),  
3.84(1H, m)



Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
					$\text{CHCl}_3$ (cm <sup>-1</sup> ): 1780, 1740(sh), 1710, 1605, 1520, $\text{IR}_{\text{max}}$ 1340
					$\text{NMR}_{\delta}$ (CDCl <sub>3</sub> ): 1.48(3H, d, J=6.4Hz), 5.25(4H, s), 6.32(2H, d, J=2Hz), 8.16(6H, d, J=8.8Hz)
					$\text{UV}_{\lambda_{\text{H}_2\text{O}}}$ nm: 297, 241
					$\text{IR}_{\text{max}}$ KBr (cm <sup>-1</sup> ): 1750, 1720, 1590, 1470, 1390, 1280
					$\text{NMR}_{\delta}$ (D <sub>2</sub> O): 1.26(3H, d, J=6.2Hz), 2.12(2H, m), 6.44(2H, t, J=2.2Hz), 7.39(2H, t, J=2.2Hz)

Example No.	R <sub>1</sub> R <sub>2</sub> R <sub>3</sub>			Y	Spectral Data
	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>		
38	PNZE	PNZ	PNB		$\text{CHCl}_3$ (cm <sup>-1</sup> ): 1780, 1750, 1700, 1650(sh), 1610, 1525, 1350 IR <sub>max</sub>
	HE	H	H		NMR $\delta$ (CDCl <sub>3</sub> ): 1.47(3H, d, J=6Hz), 5.22(4H, s), 8.12(6H, d, J=8.5Hz) UV $\lambda_{\text{max}}$ H <sub>2</sub> O nm: 298 IR <sub>max</sub> KBr (cm <sup>-1</sup> ): 1750, 1650, 1600, 1440, 1395

Example  
No.

R<sub>1</sub> R<sub>2</sub> R<sub>3</sub>


Y

Spectral Data

IR<sub>ν</sub>CHCl<sub>3</sub> (cm<sup>-1</sup>): 1783, 1750, 1715, 1660, 1615, 1530,  
max 1350

NMRδ (CDCl<sub>3</sub>): 1.48(3H, d, J=5.9Hz), 5.25(4H, s),  
8.15(6H, d, J=8.6Hz)

UVλ<sub>max</sub><sup>H<sub>2</sub>O</sup> nm: 298







IR<sub>ν</sub><sup>KBr</sup> max (cm<sup>-1</sup>): 1750, 1630, 1590, 1460, 1380, 1240,  
1090


NMRδ (D<sub>2</sub>O):

1.27(3H, d, J=6.3Hz), 3.19(1H, dd,  
J=2.9 and 9.2Hz), 3.39(1H, dd, J=2.6  
and 6.0Hz)

39

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
					IR $\nu_{\text{max}}^{\text{CHCl}_3}$ (cm <sup>-1</sup> ): 1780, 1740, 1708, 1640, 1605, 1520, 1345
	PNZE	PNZ	PNB		NMR $\delta$ (CDCl <sub>3</sub> ): 1.50(3H, d, J=6.2Hz), 5.28(4H, s), 8.19(6H, d, J=8.1Hz)
40					UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 297
	HE	H	H		IR $\nu_{\text{max}}^{\text{KBr}}$ (cm <sup>-1</sup> ): 1760, 1635, 1600, 1450, 1380
					NMR $\delta$ (D <sub>2</sub> O): 1.27(3H, d, J=6.3Hz), 3.19(1H, dd, J=2.9 and 9.1Hz), 3.39(1H, dd, J=2.7 and 6.0Hz), 3.55(2H, d, J=4.0Hz), 3.69(1H, dd, J=2.0 and 4.3Hz)

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
	PNZE	PNZ	PNB	 <chem>CC1(C)CCN(C)CC1</chem>	$\text{CHCl}_3$ (cm <sup>-1</sup> ): 1780, 1750, 1705, 1635, 1605, 1520, 1345 IR $\nu_{\text{max}}$ NMR $\delta$ (CDCl <sub>3</sub> ): 1.49(3H, d, J=6.4Hz), 5.26(4H, s), 8.20(6H, d, J=8.8Hz)
	HE	H	H	 <chem>CC1(C)CCN(C)CC1</chem>	$\text{H}_2\text{O}$ max nm: 298 UV $\lambda_{\text{max}}$ IR $\nu_{\text{max}}$ (KBr) (cm <sup>-1</sup> ): 1755, 1625, 1440, 1380, 1240 NMR $\delta$ (D <sub>2</sub> O): 1.23(3H, d, J=6.5Hz), 1.25(3H, d, J=6Hz), 1.31(3H, d, J=7Hz)

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
	PNZE	PNZ	PNB		IR $\nu_{\text{max}}^{\text{CHCl}_3}$ (cm <sup>-1</sup> ): 1785, 1746, 1705, 1657, 1610, 1525, 1345 NMR $\delta$ (CDCl <sub>3</sub> ): 1.47(3H, d, J=6.2Hz), 5.25(4H, s), 8.16(6H, d, J=8.6Hz) UV $\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 298 IR $\nu_{\text{max}}^{\text{KBr}}$ (cm <sup>-1</sup> ): 1750, 1655(sh), 1635, 1610(sh), 1380, 1220 NMR $\delta$ (D <sub>2</sub> O): 1.26(3H, d, J=6.3Hz)

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
	PNZE	PNZ	PNB	$\begin{array}{c} \text{N(CH}_3\text{)}_2 \\   \\ \text{-N=} \\   \\ \text{N(CH}_3\text{)}_2 \end{array}$	$\text{CHCl}_3$ $\text{IR } \nu_{\text{max}}$ (cm <sup>-1</sup> ): 1780, 1745, 1702, 1603, 1520, 1345  $\text{NMR } \delta$ (CDCl <sub>3</sub> ): 1.48(3H, d, J=6Hz), 2.85(6H, s), 2.93(6H, s), 5.26(4H, s)
	HE	H	H	$\begin{array}{c} \text{N(CH}_3\text{)}_2 \\   \\ \text{-N=} \\   \\ \text{N(CH}_3\text{)}_2 \end{array}$	$\text{H}_2\text{O}$ $\text{UV } \lambda_{\text{max}}$ nm: 299, 229  $\text{KBr}$ $\text{IR } \nu_{\text{max}}$ (cm <sup>-1</sup> ): 1750, 1690, 1590, 1420, 1285, 1130  $\text{NMR } \delta$ (D <sub>2</sub> O): 1.26(3H, d, J=6.3Hz), 1.91(1H, m), 2.60(1H, m), 3.08(6H, s), 3.16(6H, s), 3.40(1H, dd, J=2.7 and 6.0Hz), 4.37(1H, dd, J=6.0 and 9.5Hz)

Example  
No.

R<sub>1</sub>


R<sub>2</sub>

R<sub>3</sub>

Y

Spectral Data

PN2E PNZ PNB




IR ν<sub>max</sub><sup>CHCl<sub>3</sub></sup> (cm<sup>-1</sup>): 1780, 1740, 1705, 1605, 1523, 1345

NMR δ (CDCl<sub>3</sub>): 1.47(3H, d, J=6.8Hz), 5.25(4H, s)

UV λ<sub>max</sub><sup>H<sub>2</sub>O</sup> nm: 207, 299

HE H H



IR ν<sub>max</sub><sup>KBr</sup> (cm<sup>-1</sup>): 1750, 1640, 1590, 1545, 1385, 1040

NMR δ (D<sub>2</sub>O): 1.25(3H, d, J=6.6Hz), 1.85(1H, m)



Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
45	PNZE	PNZ	PNB	-OPNB	<p>IR ν<sub>max</sub> (cm<sup>-1</sup>): 1775(sh), 1750, 1710, 1520, 1350, 1265</p> <p>NMR δ (CDCl<sub>3</sub>): 1.48(3H, d, J=6.5Hz), 4.70(1H, dd, J=6 and 8.5Hz), 5.25(4H, s), 5.46(1H, d, J=14Hz), 7.53(4H, d, J=8.5Hz), 7.62(4H, d, J=8.5Hz), 8.18(4H, d, J=8.5Hz), 8.21(4H, d, J=8.5Hz)</p> <p>UV λ<sub>max</sub> H<sub>2</sub>O nm: 294</p>
46	PNZE	PNZ	PNB	-OCH <sub>3</sub>	<p>IR ν<sub>max</sub> CHCl<sub>3</sub> (cm<sup>-1</sup>): 1787, 1753, 1716, 1614, 1530, 1431, 1410, 1355, 1268, 1138, 1116</p> <p>NMR δ (CDCl<sub>3</sub>): 1.48(3H, d, J=6Hz), 1.83-2.42(1H, m), 2.50-3.02(1H, m), 3.17-4.53(8H, m), 3.70 and 3.73(3H, s), 5.02-5.28(2H, m), 5.27(4H, s), 5.47(1H, d, J=14Hz), 7.53(4H, d, J=9Hz), 7.63(2H, d, J=9Hz), 8.21(6H, d, J=9Hz)</p> <p>UV λ<sub>max</sub> H<sub>2</sub>O nm: 300</p>

IR ν<sub>max</sub> KBr (cm<sup>-1</sup>):

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
47	PNZE	PNZ	PNB	-NHNH <sub>2</sub>	Nujol (cm <sup>-1</sup> ): 1782, 1750, 1705, 1620, 1520, 1350 IRν <sub>max</sub> m.p. 184-187°C (dec.)
	HE	H	H	-NHNH <sub>2</sub>	H <sub>2</sub> O ν <sub>max</sub> nm: 299 KBr IRν <sub>max</sub> (cm <sup>-1</sup> ): 1750, 1720, 1590, 1390, 1245, 1120
	PNZE	PNZ	PNB	-NHN(CH <sub>3</sub> ) <sub>2</sub>	Nujol (cm <sup>-1</sup> ): 1785, 1750, 1715, 1668, 1608, 1520, 1345 IRν <sub>max</sub> m.p. 187-189°C (dec.)
	HE	H	H	-NHN(CH <sub>3</sub> ) <sub>2</sub>	H <sub>2</sub> O ν <sub>max</sub> nm: 300 KBr IRν <sub>max</sub> (cm <sup>-1</sup> ): 1750, 1690, 1595, 1390, 1175, 1020
48					NMR δ (D <sub>2</sub> O): 1.26(3H, d, J=6.4Hz), 2.60(6H, s), 3.18(1H, dd, J=6.0 and 9.1Hz), 3.39(1H, dd, J=2.6 and 6.0Hz)

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
					CHCl <sub>3</sub> (cm <sup>-1</sup> ): 1784, 1750, 1714, 1608, 1524, 1432, 1404, 1378, 1348, 1265, 1197, 1132, 1113
	PNZE	PNZ	PNB	-OC <sub>2</sub> H <sub>5</sub>	NMR δ (CDCl <sub>3</sub> ): 1.13-1.36(3H, m), 1.48(3H, d, J=6Hz), 1.83-2.36(1H, m), 2.56-3.06(1H, m), 3.19-4.59(10H, m), 4.89-5.36(2H, m), 5.27(4H, s), 5.47(1H, d, J=14Hz), 7.54(4H, d, J=8.5Hz), 7.63(2H, d, J=8.5Hz), 8.20(6H, d, J=8.5Hz)
					UV λ <sub>max</sub> <sup>H<sub>2</sub>O</sup> nm: 298
	HE	H	H	-OC <sub>2</sub> H <sub>5</sub>	IR ν <sub>max</sub> <sup>KBr</sup> (cm <sup>-1</sup> ): 1743, 1597, 1380, 1240, 1130
					NMR δ (D <sub>2</sub> O): 1.25(3H, d, J=6Hz), 1.27(3H, t, J=7Hz), 2.29(1H, m), 4.29(2H, q, J=7Hz)

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
50	PNZE	PNZ	PNB	-NHOPNB	Nujol (cm <sup>-1</sup> ): 1790, 1750, 1715, 1670, 1602, 1515, IR ν <sub>max</sub> 1340 m.p. 149-152°C (dec.)
	HE	H	H	-NHOH	UV λ <sub>max</sub> nm: 300 H <sub>2</sub> O nm: 300 KBr (cm <sup>-1</sup> ): 1750, 1680, 1600, 1400, 1120 IR ν <sub>max</sub>
	PNZE	PNZ	PNB	-NHOCH <sub>3</sub>	Nujol (cm <sup>-1</sup> ): 1787, 1745, 1710, 1665, 1605, 1520, IR ν <sub>max</sub> 1345 m.p. 188-189.5°C (dec.)
	HE	H	H	-NHOCH <sub>3</sub>	UV λ <sub>max</sub> nm: 299 H <sub>2</sub> O nm: 299 KBr (cm <sup>-1</sup> ): 1745, 1680, 1600, 1440, 1390, 1245, IR ν <sub>max</sub> 1050
51					NMR δ (D <sub>2</sub> O): 3.70(3H, s)

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
	PNZE	PNZ	PNB	$  \begin{array}{c}  \text{CH}_3 \\    \\  \text{---N---N---} \\  / \quad \backslash \\  \text{CH}_3 \quad \text{CH}_3  \end{array}  $	<p>IR<math>\nu_{\text{max}}</math> <math>\text{CHCl}_3</math> (<math>\text{cm}^{-1}</math>): 1773, 1743, 1705, 1663, 1605, 1523, 1345, 1255</p> <p>NMR<math>\delta</math> (<math>\text{CDCl}_3</math>): 1.49(3H, d, J=6.5Hz), 5.23(2H, s), 5.26(2H, s), 8.19(6H, d, J=8.8Hz)</p> <p>UV<math>\lambda_{\text{max}}</math> <math>\text{H}_2\text{O}</math> nm: 298</p> <p>IR<math>\nu_{\text{max}}</math> KBr (<math>\text{cm}^{-1}</math>): 1763, 1660, 1590, 1380, 1240, 1060</p> <p>NMR<math>\delta</math> (<math>\text{D}_2\text{O}</math>): 1.26(3H, d, J=6.6Hz), 2.50(3H, s), 2.52(3H, s), 2.92(3H, s), 3.18(2H, q, J=4.3Hz)</p>


Example  
No.

R<sub>1</sub> R<sub>2</sub> R<sub>3</sub>

Y

Spectral Data

IR<sub>ν</sub><sub>max</sub> (cm<sup>-1</sup>): 1780, 1750, 1710, 1605, 1525, 1350, 1260



PNZE PNZ PNB

NMR<sub>δ</sub> (CDCl<sub>3</sub>): 1.49(3H, d, J=6.4Hz), 5.25(4H, s), 5.36(2H, ABq, J=13.6Hz), 7.53(4H, d, J=8.8Hz), 7.62(2H, d, J=8.8Hz), 8.21(6H, d, J=8.8Hz)

53

UVλ<sub>max</sub><sup>H<sub>2</sub>O</sup> nm: 300



HE H H

IR<sub>ν</sub><sub>max</sub><sup>KBr</sup> (cm<sup>-1</sup>): 1735, 1595, 1396, 1255, 1215, 1043

Example  
No.

R<sub>1</sub>

R<sub>2</sub>

R<sub>3</sub>

Y


Spectral Data

IR<sub>ν</sub><sup>neat</sup> (cm<sup>-1</sup>): 1780, 1745, 1705, 1645, 1520, 1440,  
max 1350, 1262

NMR<sub>δ</sub> (CDCl<sub>3</sub>): 1.49(3H, d, J=6.5Hz), 5.26(4H, s  
5.24 and 5.43(2H, ABq, J=14Hz),  
7.44(2H, d, J=9Hz), 7.48(2H, d,  
J=9Hz), 7.68(2H, d, J=9Hz), 8.19(6H,  
d, J=9Hz)

UVλ<sub>max</sub><sup>H<sub>2</sub>O</sup> nm: 298

NMR<sub>δ</sub> (D<sub>2</sub>O): 1.27(3H, d, J=6Hz), 1.83(4H, t, J=7Hz),  
1.94-2.09(1H, m), 2.42(4H, t, J=7Hz),  
2.77-2.92(1H, m), 3.11-3.42(5H, m),  
3.81-3.99(1H, m), 4.14-4.29(2H, m)




PNZE PNZ PNB



HE H H


0126587



Example No.	R <sub>1</sub>	R <sub>3</sub>	A	Spectral Data
55	PNZE	PNZ		<p>IR<sub>v</sub><sup>neat</sup> (cm<sup>-1</sup>): 1775, 1745, 1700, 1520, 1345, 1260, 1130</p> <p>NMRδ (CDCl<sub>3</sub>): 1.48(3H, d, J=6.5Hz), 3.22(2H, br, d, J=9.0Hz), 5.26(4H, s), 5.25 and 5.46(2H, ABq, J=14Hz), 7.50, 7.54 and 7.60(each 2H, d, J=9.0Hz), 8.18(4H, d, J=9.0Hz), 8.21(2H, d, J=9.0Hz)</p>

[α]<sub>D</sub><sup>29</sup> +37.3° (c=0.244, acetone)

UVλ<sub>max</sub><sup>H<sub>2</sub>O</sup> nm: 298






Example  
No.

R<sub>1</sub> R<sub>3</sub>

A

Spectral Data

IR ν<sub>max</sub> (cm<sup>-1</sup>): 1780, 1745, 1700, 1610, 1520, 1400,  
1350, 1260, 1120




NMR δ (CDC<sub>2</sub>)<sub>3</sub>:

1.48(3H, d, J=6Hz), 3.19(2H, d, J=9Hz), 3.44(1H, dd, J=2.5 and 7.5Hz), 5.25(4H, s), 5.23 and 5.42(2H, ABq, J=14Hz), 7.47, 7.52 and 7.60(each 2H, d, J=8.5Hz), 8.16(4H, d, J=8.5Hz), 8.19(2H, d, J=8.5Hz)

56

PNZE PNZ



[α]<sub>D</sub><sup>32</sup> +57.6° (c=0.279, acetone)




HE H

UV λ<sub>max</sub><sup>H<sub>2</sub>O</sup> nm: 297

0126587

Example No.	R <sub>1</sub>	R <sub>2</sub>	A	Spectral Data
57	PNZE	PNB		<p>IR ν<sub>max</sub> (neat) (cm<sup>-1</sup>): 1775, 1750, 1700, 1520, 1345, 1260, 1180</p> <p>NMR δ (CDCl<sub>3</sub>): 1.48(3H, d, J=6.5Hz), 3.26(2H, br, d, J=9.0Hz), 5.25(4H, s), 5.18 and 5.46(2H, ABq, J=14Hz), 7.49, 7.53 and 7.62(each 2H, d, J=8.5Hz), 8.17(4H, d, J=8.5Hz), 8.19(2H, d, J=8.5Hz)</p> <p>[α]<sub>D</sub><sup>25</sup> +43.7° (c=0.353, acetone)</p> <p>UV λ<sub>max</sub> H<sub>2</sub>O nm: 297</p> <p>IR ν<sub>max</sub> CHCl<sub>3</sub> (cm<sup>-1</sup>): 1750, 1705, 1645, 1610, 1525, 1440, 1350, 1265</p> <p>UV λ<sub>max</sub> H<sub>2</sub>O nm: 287</p>
58	PNZE	PNB		<p>IR ν<sub>max</sub> CHCl<sub>3</sub> (cm<sup>-1</sup>): 1750, 1705, 1645, 1610, 1525, 1440, 1350, 1265</p> <p>UV λ<sub>max</sub> H<sub>2</sub>O nm: 287</p>



## Example

No.

R<sub>1</sub>R<sub>2</sub>R<sub>3</sub>

Y

Spectral Data

CHCl<sub>3</sub> (cm<sup>-1</sup>): 1775, 1700, 1607, 1520, 1395, 1345, 1105

HE

PNZ

PNB

-NH<sub>2</sub>NMRδ (CDCl<sub>3</sub>):

1.36(3H, d, J=6.0Hz), 1.37(3H, d, J=7.0Hz), 5.24(2H, s), 5.35(2H, ABq, J=13.5Hz), 7.50(2H, d, J=8.8Hz), 7.64(2H, d, J=8.8Hz) 8.22(4H, d, J=8.8Hz)

59

UVλ<sub>H<sub>2</sub>O</sub><sub>max</sub> nm: 295



HE

H

H

-NH<sub>2</sub>

KBr IR<sub>max</sub> (cm<sup>-1</sup>): 1750, 1660(sh), 1600, 1380, 1240

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
60	HE	PNZ	PNB		<p>CHCl<sub>3</sub> (cm<sup>-1</sup>): 1770, 1695, 1650, 1520, 1340</p> <p>NMRδ (CDCl<sub>3</sub>): 1.34(3H, d, J=6.15Hz), 1.36(3H, d, J=8.0Hz), 3.00(3H, s), 5.20(2H, s), 5.36(2H, ABq, J=14.0Hz), 7.47(2H, d, J=8.8Hz), 7.64(2H, d, J=8.8Hz), 8.20(2H, d, J=8.8Hz)</p>
	HE	H	H		<p>UVλ<sub>max</sub><sup>H<sub>2</sub>O</sup> nm: 289</p> <p>IRν<sub>max</sub><sup>KBr</sup> (cm<sup>-1</sup>): 1750, 1630, 1605, 1375, 1240</p>

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
	HE	PNZ	PNB	NHCH <sub>2</sub> CONH <sub>2</sub>	<p>IR <math>\nu_{\max}^{\text{CHCl}_3}</math> (cm<sup>-1</sup>): 3380, 1770, 1725(sh), 1700, 1680, 1605, 1520, 1342, 1250, 1102</p> <p>NMR <math>\delta</math> (CDCl<sub>3</sub>): 5.30(2H, s), 5.31(2H, ABq, J=13.8Hz), 7.48(2H, d, J=8.8Hz), 7.64(2H, d, J=8.8Hz), 8.21(4H, d, J=8.8Hz)</p> <p>UV <math>\lambda_{\max}^{\text{H}_2\text{O}}</math> nm: 295</p>
61	HE	H	H	NHCH <sub>2</sub> CONH <sub>2</sub>	<p>IR <math>\nu_{\max}^{\text{KBr}}</math> (cm<sup>-1</sup>): 1750, 1670, 1600, 1390, 1245</p> <p>NMR <math>\delta</math> (D<sub>2</sub>O): 1.26(3H, d, J=6.5Hz), 1.28(3H, d, J=8Hz), 3.92(2H, s)</p>

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
62	HE	PNZ	PNB	$\begin{array}{c} \text{NCH}_2\text{CONH}_2 \\   \\ \text{Me} \end{array}$	$\text{IR}_{\text{max}}^{\text{CHCl}_3} (\text{cm}^{-1}): 3480, 3350, 1773, 1678, 1604, 1525, 1345, 1310$ $\text{NMR}_{\delta} (\text{CDCl}_3): 1.34(3\text{H}, \text{d}, J=6.2\text{Hz}), 1.37(3\text{H}, \text{d}, J=7.0\text{Hz}), 3.20(3\text{H}, \text{s}), 5.18(2\text{H}, \text{s}), 5.36(2\text{H}, \text{ABq}, J=13.4\text{Hz}), 7.46(2\text{H}, \text{d}, J=8.8\text{Hz}), 7.63(2\text{H}, \text{d}, J=8.8\text{Hz}), 8.20(2\text{H}, \text{d}, J=8.8\text{Hz}), 8.21(2\text{H}, \text{d}, J=8.8\text{Hz})$ $\text{UV}_{\lambda}^{\text{H}_2\text{O}}_{\text{max}} \text{ nm}: 292$ $\text{IR}_{\text{max}}^{\text{KBr}} (\text{cm}^{-1}): 1752, 1645, 1600, 1385, 1245$
	HE	H	H	$\begin{array}{c} \text{NCH}_2\text{CONH}_2 \\   \\ \text{Me} \end{array}$	

Example  
No.

R<sub>1</sub>

R<sub>2</sub>

R<sub>3</sub>

Y

Spectral Data

IR ν<sub>max</sub> CHCl<sub>3</sub> (cm<sup>-1</sup>): 3420, 1772, 1705, 1660, 1623, 1606,  
1526, 1440, 1345

[α]<sub>D</sub><sup>25</sup> -45° (c=0.11, CHCl<sub>3</sub>)

NMR δ (CDCl<sub>3</sub>):


1.33(3H, d, J=6.15Hz), 1.37(3H, d,  
J=6.8Hz), 4.19(4H, br, s), 5.21(2H,  
s), 5.36(2H, ABq, J=13.9Hz),  
5.84(2H, s), 7.40(2H, d, J=8.6Hz),  
7.64(2H, d, J=8.6Hz), 8.14(2H, d,  
J=8.6Hz), 8.19(2H, d, J=8.6Hz)

UV λ<sub>max</sub> H<sub>2</sub>O nm: 293


IR ν<sub>max</sub> KBr (cm<sup>-1</sup>): 1750, 1640, 1610, 1460, 1380

NMR δ (D<sub>2</sub>O):

1.25(3H, d, J=6Hz), 1.27(3H, d,  
J=7.5Hz), 5.85(2H, br, s)



HE PNZ PNB



HE H H

Example  
No.

R<sub>1</sub> R<sub>2</sub> R<sub>3</sub>

Y

Spectral Data


IR  $\nu_{\max}^{\text{CHCl}_3}$  (cm<sup>-1</sup>): 1770, 1702, 1650, 1520, 1343, 1102

NMR  $\delta$  (CDCl<sub>3</sub>): 1.33(3H, d, J=6.15Hz), 1.37(3H, d, J=7.0Hz), 5.21(2H, s), 5.36(2H, ABq, J=13.9Hz), 7.50(2H, d, J=8.6Hz), 7.64(2H, d, J=8.6Hz), 8.20(4H, d, J=8.6Hz)


UV  $\lambda_{\max}^{\text{H}_2\text{O}}$  nm: 293

IR  $\nu_{\max}^{\text{KBr}}$  (cm<sup>-1</sup>): 1755, 1630(sh), 1610, 1442, 1383, 1240, 1110

NMR  $\delta$  (D<sub>2</sub>O): 1.25(3H, d, J=6.5Hz), 1.28(3H, d, J=7Hz)





HE PNZ PNB



HE H H



Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
65	HE	PNZ	PNB		$\text{IR}_{\nu_{\text{max}}}^{\text{CHCl}_3}$ ( $\text{cm}^{-1}$ ): 3400, 1770, 1705, 1650, 1520, 1432, 1345, 1107 $\text{NMR}_{\delta}^{\delta}$ ( $\text{CDCl}_3$ ): 1.35(3H, d, J=6.0Hz), 1.36(3H, d, J=7.0Hz), 5.20(2H, s), 5.36(2H, ABq, J=13.5Hz), 7.46(2H, d, J=8.8Hz), 7.64(2H, d, J=8.8Hz), 8.21(2H, d, J=8.8Hz)
	HE	H	H		$\text{UV}\lambda_{\text{max}}^{\text{H}_2\text{O}}$ nm: 293 $\text{IR}_{\nu_{\text{max}}}^{\text{KBr}}$ ( $\text{cm}^{-1}$ ): 1760, 1615, 1390, 1245, 1100

Example  
No.

R<sub>1</sub>

R<sub>2</sub>


R<sub>3</sub>

Y

Spectral Data

CHCl<sub>3</sub> (cm<sup>-1</sup>): 1770, 1705, 1656, 1525, 1345, 1112  
IR<sub>max</sub>

NMRδ (CDCl<sub>3</sub>): 1.35(3H, d, J=6.15Hz), 1.36(3H, d, J=7.0Hz), 5.22(2H, s), 5.36(2H, ABq, J=13.9Hz), 7.50(2H, d, J=8.0Hz), 7.64(2H, d, J=8.0Hz), 8.20(4H, d, J=8.0Hz)




HE PNZ PNB



66

UVλ<sub>max</sub><sup>H<sub>2</sub>O</sup> nm: 292


KBr (cm<sup>-1</sup>): 1760, 1630(sh), 1605, 1448, 1380, 1245, 1110  
IR<sub>max</sub>



HE H H

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
67	HE	PN2	PNB		IR $\nu_{\text{CHCl}_3}^{\text{max}}$ ( $\text{cm}^{-1}$ ): 1772, 1710, 1650, 1520, 1435, 1400, 1340  NMR $\delta$ ( $\text{CDCl}_3$ ): 1.34(3H) d, J=6.0Hz), 1.35(3H) d, J=7.5Hz), 2.25(3H) s), 2.31(4H) s), 5.22(2H) s), 5.36(2H) ABq, J=14.1Hz), 7.49(2H) d, J=8.6Hz), 7.63(2H) d, J=8.6Hz), 8.20(4H) d, J=8.6Hz)
	HE	H	H		UV $\lambda_{\text{H}_2\text{O}}^{\text{max}}$ nm: 291  IR $\nu_{\text{KBr}}^{\text{max}}$ ( $\text{cm}^{-1}$ ): 1755, 1620, 1442, 1380, 1250

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
68	HE	PNZ	PNB	-OCH <sub>3</sub>	<p>IR<sub>v</sub><sup>CHCl<sub>3</sub></sup> max (cm<sup>-1</sup>): 1775(sh), 1750(sh), 1710, 1605, 1522, 1345, 1107</p> <p>NMR<math>\delta</math> (CDCl<sub>3</sub>): 1.35(3H, d, J=6.4Hz), 1.36(3H, d, J=6.8Hz), 3.66 and 3.73(3H, each s), 5.24(2H, s), 5.36(2H, ABq, J=13.2Hz), 7.45(2H, d, J=8.5Hz), 7.65(2H, d, J=8.5Hz), 8.22(4H, d, J=8.5Hz)</p> <p>UV<math>\lambda</math><sub>2</sub><sup>H<sub>2</sub>O</sup> max nm: 296</p> <p>IR<sub>v</sub><sup>KBr</sup> max (cm<sup>-1</sup>): 1735, 1602, 1390</p>
	HE	H	H	-OCH <sub>3</sub>	



L-trans

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
					CHCl <sub>3</sub> (cm <sup>-1</sup> ): 3400, 1770, 1708, 1652, 1604, 1523, 1397, 1342
	HE	PNZ	PNB	-N(CH <sub>3</sub> ) <sub>2</sub>	[α] <sub>D</sub> <sup>25</sup> -33° (c=0.10, CHCl <sub>3</sub> )
69					NMRδ (CDCl <sub>3</sub> ): 1.34(3H, d, J=6.15Hz), 1.39(3H, J=7.0Hz), 2.97(3H, s), 2.91 and 3.12(3H, s), 5.21(2H, s), 5.35(2H, ABq, J=13.2Hz), 8.20(4H, d, J=8.6Hz)
					UVλ <sub>max</sub> <sup>H<sub>2</sub>O</sup> nm: 286
	HE	H	H	-N(CH <sub>3</sub> ) <sub>2</sub>	IRν <sub>max</sub> <sup>KBr</sup> (cm <sup>-1</sup> ): 1750, 1630(sh), 1610, 1395, 1250

Example  
No.

R<sub>1</sub> R<sub>2</sub> R<sub>3</sub>

Y

Spectral Data


CHCl<sub>3</sub> (cm<sup>-1</sup>): 3400, 1775, 1707, 1642, 1608, 1526  
IRν<sub>max</sub> 1445, 1345

[α]<sub>D</sub><sup>25</sup> -33° (c=0.11, CHCl<sub>3</sub>)


NMRδ (CDCl<sub>3</sub>): 1.33(3H, d, J=6.15Hz), 1.40(3H, d, J=6.8Hz), 5.20(2H, s), 5.35(2H, ABq, J=13.8Hz), 7.47(2H, d, J=8.8Hz), 7.64(2H, d, J=8.8Hz), 8.20(2H, d, J=8.8Hz)

H<sub>2</sub>O nm: 288  
UVλ<sub>max</sub>

KBr (cm<sup>-1</sup>): 1760, 1635(sh), 1610, 1450, 1380,  
IRν<sub>max</sub> 1240



HE PN2 PNB




HE H H

Example  
No.R<sub>1</sub> R<sub>2</sub> R<sub>3</sub>

Y

Spectral Data



D-trans

 $\text{IR } \nu_{\text{max}}^{\text{CHCl}_3} (\text{cm}^{-1}): 3400, 1770, 1700, 1650, 1605, 1520, 1400, 1120$ 

HE PNZ PNB

 $-\text{N}(\text{CH}_3)_2$  $\text{NMR } \delta (\text{CDCl}_3):$ 



1.33(3H, d, J=6.15Hz), 1.39(3H, d, J=6.8Hz), 2.98(3H, s), 2.92 and 3.12(3H, each s), 5.22(2H, s), 5.36(2H, ABq, J=13.5Hz), 7.50(2H, d, J=8.6Hz), 7.64(2H, d, J=8.6Hz), 8.21(4H, d, J=8.6Hz)

71


 $\text{UV } \lambda_{\text{max}}^{\text{H}_2\text{O}} \text{ nm: } 291$ 

HE H H

 $-\text{N}(\text{CH}_3)_2$ 
 $\text{IR } \nu_{\text{max}}^{\text{KBr}} (\text{cm}^{-1}): 1755, 1630(\text{sh}), 1610, 1390, 1250$

Ex mple No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
72	HE	PN2	PNB		<p>CHCl<sub>3</sub> (cm<sup>-1</sup>): 3420, 1775, 1710, 1660, 1621, 1528, 1420, 1405, 1120</p> <p>NMR δ (CDCl<sub>3</sub>): 1.33(3H, d, J=6.15Hz), 1.40(3H, d, J=6.6Hz), 4.20(2H, br, s), 5.23(2H, s), 5.84(2H, s), 7.50(2H, d, J=8.6Hz), 7.65(2H, d, J=8.6Hz), 8.15(2H, d, J=8.6Hz), 8.21(2H, d, J=8.6Hz)</p>
	HE	H	H		<p>UV λ<sub>max</sub><sup>H<sub>2</sub>O</sup> nm: 283</p> <p>IR ν<sub>max</sub><sup>KBr</sup> (cm<sup>-1</sup>): 1750, 1640, 1610, 1455, 1400, 1250</p>





D-cis

Example  
No.

R<sub>1</sub> R<sub>2</sub> R<sub>3</sub>

Y

Spectral Data

183

IR  $\nu_{\text{max}}$  CHCl<sub>3</sub> (cm<sup>-1</sup>): 3430, 1775, 1710, 1655, 1525, 1350, 1012

HE PNZ PNB

-N(CH<sub>3</sub>)<sub>2</sub>

NMR  $\delta$  (CDCl<sub>3</sub>): 1.34(3H, d, J=6.4Hz), 1.38(3H, d, J=6.8Hz), 2.92, 2.94, 2.98 and 3.08(6H, each s), 5.21(2H, s), 5.36(2H, ABq, J=13.9Hz), 7.50(2H, d, J=8.6Hz), 7.65(2H, d, J=8.6Hz), 8.21(2H, d, J=8.6Hz)

73


0126587

UV  $\lambda_{\text{max}}$  H<sub>2</sub>O nm: 297

HE H H

-N(CH<sub>3</sub>)<sub>2</sub>

IR  $\nu_{\text{max}}$  KBr (cm<sup>-1</sup>): 1755, 1630(sh), 1600, 1380, 1240



Example  
No.

R<sub>1</sub>

R<sub>2</sub>

R<sub>3</sub>

Y

Spectral Data

$[\alpha]_D^{33} +32^\circ$  (c=0.22, THF)

HE PNZ PNB -NH<sub>2</sub>

IR $\nu_{\max}^{\text{Nujol}}$  (cm<sup>-1</sup>): 1780, 1680, 1608, 1517, 1381, 1350

NMR $\delta$  (CDCl<sub>3</sub>) : 1.18(3H, d, J=6Hz), 5.22(2H, s),  
5.79(1H, s)

74

UV $\lambda_{\max}^{\text{H}_2\text{O}}$  nm: 322, 255



HE H H -NH<sub>2</sub>

IR $\nu_{\max}^{\text{KBr}}$  (cm<sup>-1</sup>): 1762, 1655, 1577, 1376


NMR $\delta$  (D<sub>2</sub>O):

1.29(3H, d, J=6.5Hz), 1.75-1.89(1H, m), 2.62-2.87(1H, m), 3.00-3.09(1H, m), 3.38-3.48(1H, m), 3.65-3.92(2H, m), 3.90(1H, dd, J=1.4Hz and J=6Hz), 4.17-4.30(1H, m), 5.68(1H, d, J=1.4Hz)

0126587

Example No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	Y	Spectral Data
					$[\alpha]_D^{27} +48^\circ$ (c=0.31, $\text{CHCl}_3$ )
	HE	PNZ	PNB		$\text{CHCl}_3$ $\text{IR}_{\text{max}} (\text{cm}^{-1})$ : 1790, 1706, 1653, 1612, 1420, 1115
					$\text{NMR}_\delta (\text{CDCl}_3)$ : 1.36(3H, d, J=6Hz), 5.22(2H, s), 5.75(1H, d, J=1.5Hz)
					$\text{KBr}$ $\text{IR}_{\text{max}} (\text{cm}^{-1})$ : 1765, 1636, 1582, 1365
	HE	H	H		$\text{NMR}_\delta (\text{D}_2\text{O})$ : 1.29(3H, d, J=6.4Hz), 1.80-2.08(5H, m), 2.88-3.05(1H, m), 3.34-3.61(5H, m), 3.64-3.74(1H, m), 3.93(1H, d, J=1.4Hz and J=6Hz), 4.04(1H, quin, J=6.6Hz), 4.24(1H, quin, J=6.3Hz), 4.40(1H, t, J=8.2Hz), 5.70(1H, d, J=1.4Hz)

0126587



Example  
No.

R<sub>1</sub>

R<sub>2</sub>

R<sub>3</sub>

Y

Spectral Data

IR<sub>max</sub> (cm<sup>-1</sup>): 1780, 1700, 1675, 1600, 1505

NMR<sub>δ</sub> (CDCl<sub>3</sub>):

4.40(1H, t, J=7Hz), 5.25(2H, s),  
5.37(1H, d, J=13.6Hz), 5.75(1H, d,  
J=1.5Hz and J=3.5Hz), 7.47(2H, d,  
J=9Hz), 7.57(2H, d, J=9Hz),  
8.16(4H, d, J=9Hz)

76


H

PNZ

PNB





-NH<sub>2</sub>














According to the procedures described in preceding Examples, the following compounds can also be prepared. In the following Tables, "Ph" means phenyl group.



Compound No.	X	Y
1	-CH <sub>2</sub> -	-NHC <sub>2</sub> H <sub>5</sub>
2	-CH <sub>2</sub> -	-NH-nC <sub>4</sub> H <sub>9</sub>
3	-CH <sub>2</sub> -	-NH-iC <sub>4</sub> H <sub>9</sub>
4	-CH <sub>2</sub> -	-N(nC <sub>3</sub> H <sub>7</sub> ) <sub>2</sub>
5	-CH <sub>2</sub> -	-N(iC <sub>3</sub> H <sub>7</sub> ) <sub>2</sub>
6	-CH <sub>2</sub> -	-N(nC <sub>4</sub> H <sub>9</sub> ) <sub>2</sub>
7	-CH <sub>2</sub> -	-N(iC <sub>4</sub> H <sub>9</sub> ) <sub>2</sub>
8	-CH <sub>2</sub> -	-N $\begin{matrix} \diagup \text{CH}_3 \\ \diagdown \text{C}_2\text{H}_5 \end{matrix}$
9	-CH <sub>2</sub> -	-N $\begin{matrix} \diagup \text{C}_2\text{H}_5 \\ \diagdown \text{nC}_4\text{H}_9 \end{matrix}$
10	-CH <sub>2</sub> -	-N $\begin{matrix} \diagup \text{---} \text{Ph} \\ \diagdown \text{H} \end{matrix}$



Compound No.	X	Y
11	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---Ph} \\   \\ \text{CH}_3 \end{array}$
12	-CH <sub>2</sub> -	$\begin{array}{c} \text{---NCH}_2\text{---Ph} \\   \\ \text{C}_2\text{H}_5 \end{array}$
13	-CH <sub>2</sub> -	-N(CH <sub>2</sub> -Ph) <sub>2</sub>
14	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---N(C}_2\text{H}_5)_2 \\   \\ \text{H} \end{array}$
15	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---N(C}_2\text{H}_5)_2 \\   \\ \text{CH}_3 \end{array}$
16	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---N(CH}_3)_2 \\   \\ \text{C}_2\text{H}_5 \end{array}$
17	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---N(C}_2\text{H}_5)_2 \\   \\ \text{C}_2\text{H}_5 \end{array}$
18	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---N(CH}_3)_2 \\   \\ \text{H} \end{array}$
19	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---N(C}_2\text{H}_5)_2 \\   \\ \text{H} \end{array}$
20	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---N(CH}_3)_2 \\   \\ \text{CH}_3 \end{array}$
21	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---N(CH}_3)_2 \\   \\ \text{C}_2\text{H}_5 \end{array}$
22	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---N(C}_2\text{H}_5)_2 \\   \\ \text{C}_2\text{H}_5 \end{array}$
23	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---OH} \\   \\ \text{CH}_3 \end{array}$






Compound No.	X	Y
24	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---CH}_2\text{---CH}_2\text{---OH} \\   \\ \text{CH}_3 \end{array}$
25	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---CH}_2\text{---CH(OH)---CH}_3 \\   \\ \text{CH}_3 \end{array}$
26	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---CH(CH}_3\text{)---CH}_2\text{---OH} \\   \\ \text{H} \end{array}$
27	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---C(CH}_3\text{)}_2\text{---CH}_2\text{---OH} \\   \\ \text{H} \end{array}$
28	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---CH}_2\text{---CH}_2\text{---OH} \\   \\ \text{C}_2\text{H}_5 \end{array}$
29	-CH <sub>2</sub> -	-N(CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> OH) <sub>2</sub>
30	-CH <sub>2</sub> -	$\begin{array}{c} \text{---N---CH}_2\text{---CH(CH}_3\text{)---CH}_2\text{---OH} \\   \\ \text{OH} \end{array}$
31	-CH <sub>2</sub> -	$\begin{array}{c} \text{CONHCH}_3 \\   \\ \text{---N---} \end{array}$ 
32	-CH <sub>2</sub> -	$\begin{array}{c} \text{CON(CH}_3\text{)}_2 \\   \\ \text{---N---} \end{array}$ 
33	-CH <sub>2</sub> -	
34	-CH <sub>2</sub> -	


Compound No.	X	Y
35	$-\text{CH}_2-$	
36	$-\text{CH}_2-$	
37	$-\text{CH}_2-$	
38	$-\text{CH}_2-$	
39	$-\text{CH}_2-$	
40	$-\text{CH}_2-$	
41	$-\text{CH}_2-$	
42	$-\text{CH}_2-$	
43	$-\text{CH}_2-$	
44		
45		











Compound No.	X	Y
46	$\begin{array}{c} \text{CH}_3 \\   \\ -\text{CH}- \end{array}$	$\begin{array}{c} -\text{NCH}_2\text{CONHCH}_3 \\   \\ \text{H} \end{array}$
47	$\begin{array}{c} \text{CH}_3 \\   \\ -\text{CH}- \end{array}$	$\begin{array}{c} -\text{NCH}_2\text{CONHCH}_3 \\   \\ \text{CH}_3 \end{array}$
48	$\begin{array}{c} \text{CH}_3 \\   \\ -\text{CH}- \end{array}$	$\begin{array}{c} \text{CONH}_2 \\   \\ \text{N} \end{array}$
49	-S-	$\begin{array}{c} \text{H} \\   \\ \text{N} \end{array}$
50	-S-	$\begin{array}{c} \text{CH}_3 \\   \\ \text{N} \end{array}$
51	-S-	$\begin{array}{c} \text{CH}_3 \\   \\ \text{N} \end{array}$
52	-S-	$\begin{array}{c} -\text{NCH}_2\text{CONH}_2 \\   \\ \text{H} \end{array}$
53	-S-	$\begin{array}{c} -\text{NCH}_2\text{CONH} \\   \\ \text{H} \end{array}$
54	-S-	$\begin{array}{c} -\text{NCH}_2\text{CONHCH}_3 \\   \\ \text{CH}_3 \end{array}$
55	-S-	$\begin{array}{c} \text{O} \\   \\ \text{N} \end{array}$
56	-S-	$\begin{array}{c} \text{N-CH}_3 \\   \\ \text{N} \end{array}$


Compound No.	X	Y
62	$\begin{array}{c} \text{CH}_3 \\   \\ -\text{CH}- \end{array}$	
63	$\begin{array}{c} \text{CH}_3 \\   \\ -\text{CH}- \end{array}$	

Compound No.	X	Y
64	-CH <sub>2</sub> -	
65	-CH <sub>2</sub> -	
66	-S-	
67	-S-	
68	-S-	
69	-S-	-N(CH <sub>3</sub> ) <sub>2</sub>









Compound No.	X	Y
70		

Compound No.	X	Y
71	$\begin{array}{c} \text{CH}_3 \\   \\ -\text{CH}- \end{array}$	
72	$-\text{CH}_2-$	
73	$-\text{CH}_2-$	
74	$-\text{S}-$	
75	$-\text{S}-$	
76	$-\text{S}-$	
77	$-\text{S}-$	$-\text{N}(\text{CH}_3)_2$



Compound No.	X	Y
78		
79		
80		
81		
82		
83		
84		


Compound No.	X	Y
85	-CH <sub>2</sub> -	
86	-CH <sub>2</sub> -	
87	-S-	
88	-S-	
89	-S-	
90	-S-	-N(CH <sub>3</sub> ) <sub>2</sub>



Compounds No.	Y
91	$-\text{NH}_2$
92	$-\text{N}(\text{CH}_3)\text{CH}_2\text{OH}$
93	$-\text{NHCH}_2\text{CONH}_2$
94	$-\text{N}(\text{CH}_3)\text{CH}_2\text{CONH}_2$
95	$-\text{N}$ (cyclopent-1-en-1-yl)
96	$-\text{N}$ (cyclobutyl)
97	$-\text{N}$ (4-hydroxycyclopentyl)
98	$-\text{N}$ (morpholinyl)
99	$-\text{N}(\text{CH}_3)$ (piperidinyl)
100	$-\text{OCH}_3$

CLAIMS:

1. A  $\beta$ -lactam compound represented by the formula:



wherein  $R_1$  represents a hydrogen atom, a 1-hydroxyethyl group or a 1-hydroxyethyl group in which the hydroxy group is protected with a protecting group;  $R_2$  represents a hydrogen atom or a protecting group for an amino group;  $R_3$  represents a hydrogen atom or a protecting group for a carboxyl group; X represents a substituted or unsubstituted methylene group of the formula (1):




wherein  $R_4$  represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, or X represents a sulfur atom; and Y represents a group of the formula (2):





wherein  $R_5$  and  $R_6$ , which may be the same or different, each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 3 to 4 carbon atoms, an aralkyl group having 1 to 3 carbon atoms in the alkyl moiety thereof, a substituted alkyl group having 1 to 5 carbon atoms or a pyridyl group, or  $R_5$  and  $R_6$  are taken together to represent an alkylene chain or an alkylene chain via an oxygen atom, a sulfur atom or a  $(C_1-C_3)$ alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, a substituted or unsubstituted 3- to 7-membered cyclic amino group which may contain double bond(s) in the ring thereof, a substituted or unsubstituted guanidyl group of the formula (3):



wherein  $R_7$  represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, a protected or unprotected hydroxyl group, an alkoxy group having 1 to 3 carbon atoms, an unsubstituted or  $(C_1-C_3)$ alkyl-substituted hydrazino group or a group of the formula (4):



wherein  $R_8$  represents a hydrogen atom, a protecting group for a hydroxyl group or an alkyl group having 1 to 3 carbon atoms, and a pharmaceutically acceptable salt thereof.

- 5      2.      A compound as claimed in Claim 1, wherein  $R_1$  represents a hydrogen atom or a 1-hydroxyethyl group,  $R_2$  and  $R_3$  each represents a hydrogen atom, and Y is a group represented by the formula (2-a):



- 10      wherein  $R_{5-a}$  and  $R_{6-a}$  each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 3 to 4 carbon atoms, an aralkyl group having 1 to 3 carbon atoms in the alkyl moiety, an alkyl group having 1 to 5 carbon atoms which is substituted with a hydroxyl group, a di-( $C_1$ - $C_3$ )alkylamino group, a carbamoyl group, a mono- or di-( $C_1$ - $C_3$ )alkyl-substituted aminocarbonyl group or a carboxyl group, or a pyridyl group; or  $R_{5-a}$  and  $R_{6-a}$  jointly represent an alkylene chain or an alkylene chain via an oxygen atom, a sulfur atom or a ( $C_1$ - $C_3$ )alkyl-substituted nitrogen atom to form, together with the adjacent nitrogen atom, an unsubstituted or substituted 3- to 7-membered cyclic amino group which may contain double bond(s) in the ring thereof wherein the substituent is an alkyl group having
- 15
- 20

1 to 3 carbon atoms, a carbamoyl group, a carboxyl group,  
 a mono- or di-(C<sub>1</sub>-C<sub>3</sub>)alkyl-substituted aminocarbonyl  
 group or a hydroxyl group; an unsubstituted or (C<sub>1</sub>-C<sub>3</sub>)alkyl-  
 substituted guanidyl group, a hydroxyl group, an alkoxy group having  
 5 1 to 3 carbon atoms, an unsubstituted or substituted  
 hydrazino group wherein the substituent is an alkyl  
 group having 1 to 3 carbon atoms; or a group represented  
 by the formula (4-a):



10 wherein R<sub>8-a</sub> represents a hydrogen atom or an alkyl group  
 having 1 to 3 carbon atoms.

3. A compound as claimed in Claim 1, wherein R<sub>1</sub>  
 represents a 1-hydroxyethyl group, R<sub>2</sub> and R<sub>3</sub> each  
 represents a hydrogen atom, and Y is a group represented  
 15 by the formula (2-b):




wherein R<sub>5-b</sub> and R<sub>6-b</sub> each represents a hydrogen atom,  
 an alkyl group having 1 to 5 carbon atoms, an alkenyl  
 group having 3 to 4 carbon atoms, an aralkyl group  
 20 having 1 to 3 carbon atoms in the alkyl moiety thereof,  
 a substituted alkyl group having 1 to 5 carbon atoms

wherein the substituent is a hydroxyl group, a di-  
 (C<sub>1</sub>-C<sub>3</sub>)alkylamino group, a carbamoyl group, a mono-  
 or di-(C<sub>1</sub>-C<sub>3</sub>)alkyl-substituted aminocarbamoyl group or  
 a carboxyl group, or a pyridyl group, or R<sub>5-b</sub> and R<sub>6-b</sub>  
 5 jointly represent an alkylene chain or an alkylene chain  
 via an oxygen atom, a sulfur atom or a (C<sub>1</sub>-C<sub>3</sub>)alkyl-  
 substituted nitrogen atom to form, together with the  
 adjacent nitrogen atom, an unsubstituted or substituted  
 3- to 7-membered cyclic amino group which may contain  
 10 double bond(s) in the ring thereof wherein the substituent  
 is an alkyl group having 1 to 3 carbon atoms, a carbamoyl  
 group or a hydroxyl group; an unsubstituted or substituted  
 guanidyl group wherein the substituent is an alkyl group  
 having 1 to 3 carbon atoms; a  
 15 hydroxyl group, an alkoxy group having 1 to 3 carbon  
 atoms, an unsubstituted or substituted hydrazino group  
 wherein the substituent is an alkyl group having 1 to 3  
 carbon atoms; or a group represented by the formula (4-a):



20 wherein R<sub>8-a</sub> represents a hydrogen atom or an alkyl  
 group having 1 to 3 carbon atoms.

4. A compound as claimed in Claim 1, wherein  $R_1$  represents a 1-hydroxyethyl group,  $R_2$  and  $R_3$  each represents a hydrogen atom, and Y is a group represented by the formula (2-c):



wherein  $R_{5-C}$  and  $R_{6-C}$  have one of the following meanings:

(1)  $R_{5-C}$  represents an alkyl group having 1 to 5 carbon atoms which may be substituted with a carbamoyl group, a mono- or di- $(C_1-C_3)$ alkylamino-carbonyl group or a hydroxyl group, or a pyridyl group, and  $R_{6-C}$  represents a hydrogen atom or has the same meaning as defined for  $R_{5-C}$ ;

(2)  $R_{5-C}$  and  $R_{6-C}$  jointly represent an alkylene chain to form, together with the adjacent nitrogen atom, an unsubstituted or substituted 4- to 6-membered saturated cyclic amino group or an unsubstituted or substituted 5- to 6-membered cyclic amino group having double bond(s) in the ring thereof wherein the substituent on the cyclic amino ring is a carbamoyl group or a hydroxyl group; and

(3)  $R_{5-C}$  and  $R_{6-C}$  jointly represent an alkylene chain via an oxygen atom or a  $(C_1-C_3)$ alkyl-substituted nitrogen atom to form, together with

acceptable salt thereof.

17. (5R)-3-[2-((1-Pyrroli-3-nyl)carbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

18. (5R)-3-[2-((1-Azetidino)carbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceuticaly acceptable salt thereof.

19. (5R)-3-[2-((3-Hydroxy-1-pyrrolidino)carbonyl)-pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

20. (5R)-3-[2-((2-Hydroxyethyl)methylaminocarbonyl)-pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-3-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

21. (5R)-3-[2-(1-Morpholinocarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

22. (5R)-3-[2-(1-N-Methylpiperazinocarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceuticaly acceptable salt thereof.

pharmaceutically acceptable salt thereof.

30. (5R)-3-[2-((3-Hydroxy-1-pyrrolidino)carbonyl)-pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid,

5 or a non-toxic pharmaceutically acceptable salt thereof.

31. (5R)-3-[2-((2-Hydroxyethyl)methylaminocarbonyl)-pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or

a non-toxic pharmaceutically acceptable salt thereof.

10 32. (5R)-3-[2-(1-Morpholinocarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

33. (5R)-3-[2-(1-N-Methylpiperazinocarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

34. (5R)-3-[2-Carbamoylpyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

35. (5R)-3-[2-(Methoxycarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.

36. A (5R,6S,8R)-compound of a compound as claimed in any one of Claims 3 to 35.

23. (5R)-3-[2-(Methoxycarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
- 5 24. (5R)-3-[2-Carbamoylpyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
- 10 25. (5R)-3-[2-(4-Pyridylaminocarbonyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
- 15 26. (5R)-3-[2-(Dimethylaminocarbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
- 20 27. (5R)-3-[2-((1-pyrrolidino)carbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
28. (5R)-3-[2-((1-Pyrroli-3-nyl)carbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic pharmaceutically acceptable salt thereof.
- 25 29. (5R)-3-[2-((1-Azatidino)carbonyl)pyrrolidin-4-ylthio]-4-methyl-6-(1-hydroxyethyl)-1-azabicyclo[3,2,0]hept-2-ene-7-one-2-carboxylic acid, or a non-toxic



37. A (5R,6S,8R,2'S,4'S)-compound of a compound as claimed in any one of Claims 3 to 35.

38. A (4R,5R,6S,8R,2'S,4'S)-compound of a compound as claimed in any one of Claims 3 to 8 and 26 to 35.


5

39. A pharmaceutical composition which comprises as an active ingredient a pharmaceutically effective amount of at least one of the compounds as claimed in any preceding claim and at least one pharmaceutically acceptable inert carrier or diluent.


10

40. Use of a compound according to Claim 1 as an antimicrobial agent.

41. A process for preparing a compound as claimed in Claim 1, which comprises reacting a compound of the formula (II):



5 wherein  $R_1$  and X are as defined in Claim 1,  $R_9$  represents a protecting group for a carboxyl group, Z represents a reactive ester of an alcohol, or a substituted or unsubstituted lower-alkyl sulfinyl group, with a mercaptan derivative of the formula:



wherein  $R_2$  is as defined in Claim 1, and Y' is a group represented by the formula (2):




15 wherein  $R_5$  and  $R_6$  are as defined above, an unsubstituted or alkyl-substituted guanidyl group having 1 to 3 carbon atoms in the alkyl moiety, a hydroxyl group protected with a carboxyl protecting group, an alkoxy group having 1 to 3 carbon

atoms, an unsubstituted or substituted hydrazino group wherein the substituent is an alkyl group having 1 to 3 carbon atoms, or a group represented by the formula (4'):



5 wherein  $R_8'$  represents a protecting group for a hydroxyl group or an alkyl group having 1 to 3 carbon atoms, in the presence of a base in an inert solvent to produce a  $\beta$ -lactam compound represented by the formula (IV):



10 wherein  $R_1$ ,  $R_2$ ,  $R_9$ ,  $X$  and  $Y'$  are as defined above, and, if desired, subjecting the resulting compound to an appropriate combination of removal of the protecting group for the carboxyl group, the protecting group for the hydroxyl group and/or the protecting group for the amino group, sequentially or simultaneously, to produce  
15 the compound of the formula (IV) wherein  $R_1$  is a 1-hydroxyethyl group,  $R_2$  is a hydrogen atom and/or  $R_3$  is a hydrogen atom, or the compound of the formula (IV) wherein the protecting group on the group  $Y'$  is removed.



European Patent  
Office

# EUROPEAN SEARCH REPORT

0126587

Application number

EP 84 30 3128

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 3)
Y	CHEMICAL ABSTRACTS, vol. 98, no. 17, 25th April 1983, page 557, no. 143190w, Columbus, Ohio, US; & JP - A - 57 176 988 (SANKYO CO., LTD.) 30-10-1982 * Abstract *	1, 10, 39-41	C 07 D 487/04 C 07 D 499/00 A 61 K 31/40 A 61 K 31/43 C 07 D 207/16 C 07 D 207/24 C 07 D 401/12 C 07 D 205/08 C 07 F 7/18 C 07 F 9/65 (C 07 D 487/04 C 07 D 209/00 C 07 D 205/00 )
Y	EP-A-O 002 210 (MERCK) * Claims *	1, 10, 39-41	
Y	EP-A-O 072 710 (SANKYO) * Claims *	1, 7, 39-41	
Y	EP-A-O 017 992 (MERCK) * Claims and especially claims 8, 22 on page 237 above and claim 28 on page 270 above *	1, 7, 39-41	TECHNICAL FIELDS SEARCHED (Int. Cl. 3)  C 07 D 487/00 C 07 D 499/00 A 61 K 31/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 09-07-1984	Examiner CHOULY J.
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			